Document:

exv10w23

    EXHIBIT 10.23

 

    Conexant
    Systems, Inc.

    

 

    Board of
    Directors Annual Remuneration

    

    As of
    August 10, 2010

 

    Cash
    Compensation

 

    The cash compensation of non-employee Directors is as follows:

 

	 	 	 	 	 
	

    Type

	
 
	
    Amount
	
 

	
 
	
 
	
    (In dollars)
	
 

	 

	

    Annual

	

    Board
    membership1

	
 
	
 
	
    30,000
	
 

	

    Committee membership

	
 
	
 
	
    7,500
	
 

	

    Committee Chair — Audit Committee

	
 
	
 
	
    20,000
	
 

	

    Committee Chair — all other committees

	
 
	
 
	
    15,000
	
 

	

    Lead Independent Director

	
 
	
 
	
    15,000
	
 

	
 

	

    Meeting Attendance

	

    Board meeting

	
 
	
 
	
    1,500
	
 

	

    Committee meeting

	
 
	
 
	
    1,000
	
 

 

    The retainers and fees are payable as follows:

 

    (i) Base and Committee chairmanship and membership annual
    retainers and the retainer for the Lead Independent
    Director — in cash quarterly in advance; unless a
    director elects to take payment in Shares under the provisions
    of Section 7 of the Directors Plan (attached hereto); a
    director electing to take payment in Shares will be issued his
    shares on the same date as the cash retainer and applicable
    meeting fees are paid to non-electing directors; and

 

    (ii) Meeting fees — quarterly in arrears.

 

    Directors are also reimbursed for travel, transportation
    (including personal automobile mileage at the maximum per mile
    rate set by the Internal Revenue Service), other expenses
    actually incurred in attending Board and Committee meetings, and
    the cost of continuing education (one course every three years).
    In addition, the Company will match a director’s
    contributions to educational institutions up to $5,000 per
    fiscal year.

 

    Equity
    Compensation

 

    On February 18, 2009, the Board suspended indefinitely the
    payment of any equity compensation under the Directors Stock
    Plan.

 

    Under the Directors Stock Plan, upon initial election to the
    Board, each non-employee Director shall be granted an option to
    purchase 40,000 shares of the Corporation’s Common
    Stock at the closing price per share (the Fair Market Value) on
    the date of grant as reported in the Nasdaq reporting system (or
    on the next preceding day such stock was traded if it was not
    traded on the date of grant). Thereafter, each non-employee
    Director who has served as a non-employee Director for at least
    six (6) months and is elected a director at, or who was
    previously elected and continues as a director after, that
    Annual Meeting shall be granted:

 

			
	 	    • 
	
    an option to purchase 10,000 shares on the day of the
    Annual Meeting of Shareowners (“First Annual
    Grant”); and

	 
	 	    • 
	
    an option to purchase 10,000 shares six (6) months
    after the First Annual Grant (“Second Annual Grant”);

 

 

    1 Any

    directors appointed to the Board from May 30, 2008 through
    the February 18, 2009 were entitled to receive a one-time
    Supplemental payment of $50,000.

 

 

    provided that the Board may, by action taken on or the date of
    any such Annual Meeting, defer the First Annual Grant for up to
    forty-five (45) days following such Annual Meeting and may
    defer the Second Annual Grant up to forty-five (45) days
    before or after the six (6) month anniversary of the First
    Annual Grant.

 

    These stock options become exercisable in four
    (4) approximately equal annual installments and are
    exercisable during a Director’s Board service for up to ten
    (10) years after the grant date.

 

    A Director who retires from the Board with at least five
    (5) years of Board service may exercise all remaining stock
    options granted (whether or not otherwise exercisable) for up to
    five (5) years after his or her retirement date (or the
    expiration date specified in the option). If a Director dies
    while serving on the Board, his or her estate, heirs or legatees
    (or a permitted assignee) may exercise all remaining stock
    options (whether or not otherwise exercisable) for up to three
    (3) years after the Director’s date of death (or the
    expiration date specified in the option ). A Director who
    becomes disabled or resigns for reasons of the antitrust laws,
    compliance with the Corporation’s conflict of interest
    policies or other circumstances that the Compensation and
    Management Development Committee (the Committee) may determine
    as serving the best interests of the Corporation may exercise
    his or her remaining stock options to the extent exercisable at
    the date of termination of his or her Board service for such
    period after that date as the Committee may determine (or the
    expiration date specified in the option).

 

    If a Change of Control occurs, as defined in the Bylaws, all
    stock options outstanding under the Directors Stock Plan become
    fully exercisable (whether or not otherwise then exercisable)
    and each such option shall expire at the earlier of five
    (5) years from the date of the Change of Control or the
    expiration date specified in the option. In all other cases, a
    Director’s stock options expire upon termination of his or
    her Board service.

 

    Director stock options are not transferable except by will or
    the laws governing intestate succession or by gift to a
    Director’s spouse or natural, adopted or stepchildren or
    grandchildren. In addition, any Director may transfer any stock
    options granted under the Plan to any entity affiliated with the
    Director, to be designated in writing by the Director and
    approved by the Board, all such transfers to be subject to the
    same terms and conditions as the original grant made directly to
    the individual Director.

    

    2exv10w2

Exhibit 10.2

AMENDMENT NO. 2 TO OTC LICENSE AGREEMENT

     This Amendment No. 2 (the “Amendment”) to the OTC License Agreement dated October 17, 2006,
between Schering-Plough Healthcare Products, Inc. (“MCC”) and Santarus, Inc. (“Santarus”), as
amended, (the “License”) is made as of August 6, 2010.

RECITALS

     WHEREAS, MCC desires to reallocate, within the Marketing Commitment for the Licensed Product,
some of the amounts budgeted without affecting the Net Sales amount on which Santarus is paid a
royalty; and

     WHEREAS, MCC and Santarus desire to amend certain terms of the License to account for those
circumstances, as set forth herein.

     NOW, THEREFORE, for and in consideration of the covenants, conditions, and undertakings
hereinafter set forth, the Parties agree as follows:

AGREEMENT

     1. Amendment of Section 1.21. Section 1.21 of the License is hereby amended by
deleting the definition of “Marketing Commitment” and replacing it with: “means the out-of-pocket
amount incurred by Schering to market the first Licensed Product (in each case, to the extent not
deducted from gross sales in determination of Net Sales), including marketing programs, consumer
promotions, consumer advertising, consumer events, product public relations (excluding general
corporate public relations), product display and trade promotion, as well as Emerging Issues Task
Force (EITF) trade and consumer allowances. It is understood that amounts incurred for EITF trade
and consumer allowances may be counted toward the Marketing Commitment even if deducted from gross
sales (see §1.24 “Net Sales”) of Licensed Products, as long as MCC adjusts the royalty paid to
Santarus so that the royalty payment received by Santarus is not adversely affected.”

     2. Miscellaneous.

          a. THIS AMENDMENT AND THE LICENSE AS AMENDED BY THIS AMENDMENT SETS FORTH THE ENTIRE AGREEMENT
AND UNDERSTANDING OF MCC AND SANTARUS WITH RESPECT TO THE SUBJECT MATTER HEREOF, AND SUPERCEDES ALL
PRIOR DISCUSSIONS, AGREEMENTS AND WRITINGS IN RELATION THERETO. EXCEPT AS OTHERWISE EXPRESSLY SET
FORTH IN THE LICENSE, THE PARTIES HAVE NOT RELIED ON ANY MATERIAL REPRESENTATIONS OR WARRANTIES IN
CONNECTION WITH THE NEGOTIATION AND EXECUTION OF THIS AMENDMENT.

          b. Except for the amendments set forth herein, all other terms and conditions of the License
shall remain in full force and effect.

1

 

          c. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to
them in the License.

     IN WITNESS WHEREOF, the Parties have duly executed this Amendment to be effective as of August
6, 2010.

	 	 	 	 	 
	SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC.

 	 
	By:  	/s/ Thomas J. Higgins
 	 
	 	Name:  	Thomas J. Higgins           	 
	 	Title:  	VP 	 
	 
	SANTARUS, INC.

 	 
	By:  	/s/ Gerald T. Proehl
 	 
	 	Name:  	Gerald T. Proehl 	 
	 	Title:  	President and CEO 	 
	 

2exv10w3

Exhibit 10.3

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.

DISTRIBUTION AND LICENSE AGREEMENT

     This DISTRIBUTION AND LICENSE AGREEMENT (this “Agreement”) is made as of September 3,
2010 (the “Effective Date”), by and among VeroScience, LLC, a Delaware limited liability
company (“VeroScience”), S2 Therapeutics, Inc. f/k/a Wythe Therapeutics, Inc., a Tennessee
corporation (“S2”), and Santarus, Inc., a Delaware corporation (“Santarus”). Each
of VeroScience, S2 and Santarus is referred to herein individually as a “party” and
collectively as the “parties.”

     WHEREAS, VeroScience has developed the Product, is the owner of the NDA and the Product
Trademarks, and owns or Controls the intellectual property used in making, having made, using,
selling and importing the Product, subject to the terms and conditions of the S2/Vero Agreement;

     WHEREAS, VeroScience previously granted to S2 the exclusive rights to market and distribute
the Product in the Territory, pursuant to the terms and conditions of the S2/Vero Agreement; and

     WHEREAS, VeroScience and S2 desire to grant and exclusively license or sublicense, as
applicable, to Santarus rights to manufacture, market and distribute the Product in the Territory,
and Santarus desires to manufacture, market and distribute the Product in the Territory, all in
accordance with the terms and conditions contained herein.

     NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants herein
contained, the parties hereto intending to be legally bound hereby agree as follows:

ARTICLE I

DEFINITIONS

     As used in this Agreement, the following terms shall have the following meanings:

     1.1 “Act” means the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. 301,
et. seq., as it may be amended from time to time, and the regulations promulgated thereunder.

     1.2 “Additional Product(s)” shall have the meaning set forth in Section 2.5(b).

     1.3 “Advance” has the meaning set forth in Section 7.1(a).

     1.4 “Adverse Drug Experience” means any “adverse drug experience” as defined or
contemplated by 21 C.F.R. 314.80 or 312.32, associated with the Product.

     1.5 “Adverse Drug Experience Report” means any oral, written or electronic report of
any Adverse Drug Experience transmitted to any Person.

 

 

     1.6 “Affiliate” means, with respect to any Person, any other Person that directly or
indirectly controls, is controlled by or is under common control with, such first Person. For the
purposes of this definition, “control” (including, with correlative meanings, the terms
“controlling,” “controlled by” and “under common control with”), as applied to any Person, means
the possession, directly or indirectly, of the power to direct or cause the direction of the
management and policies of that Person, whether through the ownership of voting securities, by
contract or otherwise.

     1.7 “Agreement” has the meaning set forth in the preamble to this Agreement.

     1.8 “Agreement Month” means each calendar month during the Term (including any partial
calendar month in the case of the first and last calendar months of the Term).

     1.9 “Agreement Quarter” means the Initial Agreement Quarter, each successive period of
three months during the Term after the Initial Agreement Quarter and the Final Agreement Quarter.

     1.10 “Annual Plan” has the meaning set forth in Section 4.5.

     1.11 “cGMP” shall mean current “Good Manufacturing Practices” as such term is defined
from time to time by the FDA or other relevant Governmental Authority having jurisdiction over the
manufacture or sale of the Product pursuant to its regulations, guidelines or otherwise.

     1.12 “Co-Chairs” has the meaning set forth in Section 3.1(b).

     1.13 “COGS” means, for a particular period, Cost of Goods (as defined below) to
manufacture Product for sale in the Territory. For purposes of this definition, “Cost of Goods”
means Santarus’s costs of goods sold, calculated in accordance with Santarus’s standard accounting
principles and GAAP, consistently applied, including labor and material cost, allocable
depreciation and amortization, product quality assurance/control costs, allocable facilities costs
(e.g., sewer, water, property taxes), insurance, costs actually paid to contract manufacturers
(without mark-up) and other costs borne by Santarus for transport, customs and duty clearance and
storage, in each case, to the extent permitted under GAAP and of Product manufactured for sale in
the Territory. “Cost of Goods” shall exclude costs and charges related to or occasioned by (i)
unused manufacturing capacity not reserved for the production of Product in the Territory; (ii)
allocation of general corporate overhead; and (iii) license fees, royalties or other amounts paid
or payable by S2 or VeroScience in connection with the sale of Product in the Territory pursuant to
the Upstream Agreements or otherwise.

     1.14 “Commercialization”, “Commercializing” or “Commercialize” means
activities directed to marketing, Promoting, offering to sell and/or selling the Product.

     1.15 “Commercially Reasonable Efforts” means, with respect to a party and a given
pharmaceutical product, the efforts and resources which would be used (including the promptness in
which such efforts and resources would be applied) by such party relating to a

2

 

given activity or activities, consistent with its normal business practices, which is consistent
with the general level of effort and resources in the pharmaceutical industry for such activity or
activities, for a pharmaceutical product owned by it or to which it has similar rights, with
similar product characteristics, which is of similar market potential at a similar stage in its
development or product life, taking into account the proprietary position of the compound or
product and the potential or actual profitability of the applicable product.

     1.16 “Confidentiality Agreements” means that certain Confidentiality Agreement, dated
February 28, 2008 between Santarus and VeroScience and that certain Confidentiality Agreement dated
June 30, 2009 between Santarus and S2.

     1.17 “Control” or “Controlled” means, with respect to patents, trade secrets,
know-how or other intellectual property rights of any kind, the possession by a party of the
ability to grant a license or sublicense of such rights without the payment of additional
consideration, other than as set forth on Schedule 1.17, and without violating the terms of
any agreement or arrangement between such party and any Third Party.

     1.18 “DDMAC” means the FDA’s Division of Drug Marketing, Advertising and
Communications, or any successor Governmental Authority performing comparable functions in the
Territory.

     1.19 “Details” means in-person, face-to-face sales presentations of the Product made
by sales representatives, which presentations are for the purpose of promoting the sale of the
Product.

     1.20 “Development” has the meaning set forth in Section 2.5(d).

     1.21 “Effective Date” has the meaning set forth in the preamble to this Agreement.

     1.22 “Enforcement Action” has the meaning set forth in Section 10.3(b).

     1.23 “Excluded Additional Product” has the meaning set forth in Section 2.5(b).

     1.24 “Executive Officers” means the Chief Executive Officers of Santarus, S2 and
VeroScience (or, if there is no such officer of a particular party, its President) or any other
executive officer designated by the Chief Executive Officer of Santarus, S2 or VeroScience, as
applicable, or by such party.

     1.25 “FDA” means the United States Food and Drug Administration or any successor
agency performing comparable functions in the Territory.

     1.26 “Field” has the meaning set forth in Section 2.4(b).

     1.27 “Final Agreement Quarter” means the period commencing on the first day following
the last full Agreement Quarter during the Term and ending on the last day of the Term.

3

 

     1.28 “Force Majeure Event” has the meaning set forth in Section 15.7.

     1.29 “GAAP” has the meaning set forth in Section 7.2(c).

     1.30 “Generic Drug Act” has the meaning set forth in Section 9.1(j).

     1.31 “Generic Product” has the meaning set forth in Section 8.2(c).

     1.32 “Governmental Authority” shall mean any court, agency, authority, department,
regulatory body or other instrumentality of any government or country or of any national, federal,
state, provincial, regional, county, city or other political subdivision of any such government or
any supranational organization of which any such country is a member, which has competent and
binding authority to decide, mandate, regulate, enforce, or otherwise control the activities of the
parties contemplated by this Agreement.

     1.33 “Gross Margin” means, for a particular period, (A) Net Sales for such period
minus (B) COGS for such period.

     1.34 “Included Additional Product” has the meaning set forth in Section 2.5(b).

     1.35 “Initial Agreement Quarter” means the period commencing on the Effective Date and
ending on September 30, 2010.

     1.36 “Initial Fee” has the meaning set forth in Section
7.1(a).

     1.37 “JSC” has the meaning set forth in Section 3.1.

     1.38 “Launch Period” means the first six (6) Agreement Months following the
Promotion Commencement Date.

     1.39 “Legal Requirements” means laws, rules and regulations of any Governmental
Authority in the Territory, including, for clarity, all guidelines, policies and procedures
referenced in Section 5.3 of this Agreement.

     1.40 “Listed Patents” has the meaning set forth in Section 9.1(f).

     1.41 “Manufacture” or “Manufacturing” means, with respect to the Product,
process scale-up, validation, clinical and commercial manufacturing (including bulk manufacturing
and finished pharmaceutical product manufacturing).

     1.42 “NDA” means any “new drug application” (as such term is used under the Act) filed
or acquired by VeroScience or S2 and approved by the FDA with respect to the Product and all
subsequent submissions, supplements and amendments thereto, including NDA No. 20,866 filed by
VeroScience with the FDA on August 22, 1997 and approved by the FDA on May 5, 2009 (as such NDA may
be amended or supplemented subsequent to the approval date); provided, that as used hereunder,
“NDA” (including references to “NDA No. 20,866”) shall not

4

 

include any NDA or submission approved by the FDA with respect to Additional Products unless
otherwise agreed by the parties pursuant to Section 2.5(b).

     1.43 “Net Sales” means, with respect to a particular period, the amount invoiced and
recognized as sales of the Product by Santarus, its Affiliates or its sublicensees to a Third Party
in the Territory, less (i) all allowances for discounts, rebates and charge-backs, including
wholesaler fees and prompt pay discounts, (ii) credits or allowances actually granted upon claims,
rejections or returns of Product, (iii) freight, postage, shipping and insurance charges paid for
delivery of Product when included in billing, and (iv) taxes, duties or other governmental charges
levied on or measured by the billing amount when included in billing, as adjusted for rebates and
refunds, all as calculated in accordance with Santarus’ standard accounting principles and GAAP,
consistently applied. “Net Sales” shall not include (i) sales or transfers to an Affiliate or
sublicensee (but the sale or resale by such Affiliate or sublicensee shall be considered a sale),
(ii) distribution of Samples or (iii) not-for-value transfers for clinical or compassionate use.

     1.44 “Order” means any award, decision, injunction, judgment, decree, order, ruling,
or verdict entered, issued, made, or rendered by any Governmental Authority or by any arbitrator.

     1.45 “Paragraph IV Notice” has the meaning set forth in Section 10.3(a).

     1.46 “Patents” means all patents and patent applications heretofore or hereafter
having legal force in any country together with any and all patents that have issued or in the
future issue therefrom, including any and all divisionals, continuations, continuations-in-part,
reexamination certificates, extensions, supplementary protection certificates, patents of addition,
certificates of invention, utility model and design patents, substitutions, renewals, reissues or
additions of or relating to any of the aforesaid patents and patent applications.

     1.47 “Patheon Agreement” means that certain Manufacturing Services Agreement, dated as
of May 26, 2010, between S2 and Patheon, as amended from time to time. “Patheon” means Patheon
Pharmaceuticals Inc. or any successor or assign.

     1.48 “PDMA” means the Prescription Drug Marketing Act, as amended, and the rules and
regulations promulgated thereunder.

     1.49 “Person” means any individual, corporation (including any non-profit
corporation), general or limited partnership, limited liability company, joint venture,
estate, trust, association, organization, labor union, or other entity or Governmental
Authority.

     1.50 “Pliva” means PLIVA ISTRAŽIVANJE I RAZVOJ d.o.o. and its Affiliates.

     1.51 “Post-Approval Commitments” has the meaning set forth in Section 2.5(a).

     1.52 “Prescription Data” means data provided by a Third Party which measures
prescriptions filled for Product in the Territory during a specified time period, from a source

5

 

mutually agreed in writing by the parties (it being understood that each of IMS Health
Incorporated and Wolters Kluwer is a source agreeable to the parties).

     1.53 “Product” means the pharmaceutical product formulation for human use containing
bromocriptine mesylate as the sole active ingredient which is known as Cycloset, as of the
Effective Date, as more particularly described in NDA No. 20,866 filed by VeroScience with the FDA
on August 22, 1997 and approved by the FDA on May 5, 2009 (as such NDA has been or may be amended
or supplemented), including the Product as it exists on the Effective Date with modifications to
dosage strength, modifications of excipients exclusively for the treatment of type 2 diabetes, or
conversion of dosage form, for instance, to a capsule or caplet, but not including any Additional
Product, unless mutually agreed by the parties pursuant to Section 2.5(b).

     1.54 “Product Complaints” means any report concerning the quality, purity, quantity,
weight, pharmacologic activity, labeling, identity or appearance of the Product.

     1.55 “Product Royalty” has the meaning set forth in Section 7.1(b).

     1.56 “Product Trademarks” means (a) the VeroScience and Cycloset trademarks as set
forth on Schedule 1.56, (b) the domain name “cycloset.com”, and (c) all related domain
names and other trademark related rights.

     1.57 “Professional” means a physician or other health care practitioner who is
permitted by law to prescribe Product.

     1.58 “Promote,” “Promoting,” “Promotional” and “Promotion”
mean, with respect to the Product, any activities undertaken to encourage sales or use of such
Product, including Details, product sampling, detail aids, drop-offs, coupons, discount cards,
non-CME medical education, journal advertising, direct mail programs, direct-to-consumer
advertising, convention exhibits and all other forms of marketing, advertising, public relations or
promotion.

     1.59 “Promotion Commencement Date” means [***].

     1.60 “Promotional Materials” has the meaning set forth in Section 4.4.

     1.61 “Proprietary Information” means any proprietary or confidential information
communicated from one party to another in connection with or relating to this Agreement or the
Product, which is identified as confidential or proprietary, or which the other party knows or has
reason to know is confidential or proprietary, including the Technology and financial, marketing,
business, technical and scientific information or data (including the VeroScience Financials and S2
Financials) and information contained within the Annual Plan or other reports provided by Santarus
to the other parties hereunder, whether communicated in writing, orally or electronically.
Proprietary Information shall not include information that the receiving party can show through
written documentation:

     (a) at the time of disclosure, is publicly known;

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

6

 

     (b) after the time of disclosure, becomes part of the public domain without breach of an
obligation of confidentiality with respect thereto;

     (c) is or was in the possession of the receiving party or any Affiliate thereof at the time of
disclosure by the disclosing party and was not acquired directly or indirectly from the disclosing
party or any Affiliate thereof or from any other Person under an agreement of confidentiality to
the disclosing party or any Affiliate thereof; or

     (d) is or was developed by the receiving party or its Affiliates without use of or reference
to another party’s Proprietary Information.

     1.62 “Regulatory Amounts” has the meaning set forth in Section 7.1(a)(iv).

     1.63 “Regulatory Approval” means any and all consents or other authorizations or
approvals required from the FDA to market and sell the Product in the Territory.

     1.64 “Restricted Term” has the meaning set forth in Section 2.4(b).

     1.65 “Royalty True-Up” has the meaning set forth in Section 7.1(b).

     1.66 “S2” has the meaning set forth in the preamble to this Agreement.

     1.67 “S2 Co-Promotion Right” has the meaning set forth in Section 2.1(b).

     1.68 “S2 Financials” has the meaning set forth in Section 9.1(i).

     1.69 “S2/Vero Agreement” means that certain Exclusive License, Marketing, and
Distribution Agreement between VeroScience and S2, dated March 23, 2006, as amended on April 5,
2006, May 10, 2006 and the Effective Date, and as further amended from time to time as permitted
under this Agreement.

     1.70 “S2/Vero Amendment No. 3” means that certain Amendment No. 3 to Exclusive
License, Marketing and Distribution Agreement between VeroScience and S2, dated the Effective Date.

     1.71 “Safety Stock” has the meaning set forth in Section 6.1(b).

     1.72 “Samples” has the meaning set forth in Section 6.4(a).

     1.73 “Santarus” has the meaning set forth in the Preamble to this Agreement.

     1.74 “Santarus Sales Force” means the field force of sales representatives employed or
engaged by Santarus, including field-based sales force management such as regional and district
sales managers.

     1.75 “Santarus Trademarks” means the trademarks set forth on Schedule 1.75,
including the “Santarus” trademark and associated design and logo.

7

 

     1.76 “Serious Adverse Drug Experience” means any Adverse Drug Experience, including
those subject to expedited reporting as defined in the regulations cited below, that is fatal or
life-threatening, requires hospitalization or prolongation of existing hospitalization, results in
persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is of
comparable medical significance or any other event which would constitute a “serious” Adverse Drug
Experience pursuant to the terms of 21 C.F.R. 314.80 or 312.32.

     1.77 “Serious Adverse Drug Experience Report” means any Adverse Drug Experience Report
that involves a Serious Adverse Drug Experience.

     1.78 “Supplemental Patheon Agreements” has the meaning set forth in Section 9.1(m).

     1.79 “Supply Agreements” means (a) the Patheon Agreement and the Supplemental Patheon
Agreements; and (b) any additional supply agreements, exclusively relating to the Product, entered
into by Santarus following the Effective Date.

     1.80 “Technology” means all pharmacological, toxicological, preclinical, clinical,
technical or other information, data and analysis and know-how relating to the registration,
manufacture, packaging, use, marketing or sale of the Product and all proprietary rights relating
thereto owned or Controlled by S2 or VeroScience or their respective Affiliates or to which S2 or
VeroScience or their respective Affiliates has rights so as to be able to license or sublicense, as
applicable.

     1.81 “Term” has the meaning set forth in Section 8.1.

     1.82 “Territory” means the United States, including its territories and possessions
and Puerto Rico.

     1.83 “Third Party” means any Person other than Santarus, S2 or VeroScience or their
respective Affiliates.

     1.84 “Third Party Rights Holders” means Ergo Research (Nevada) Corp., Ergo Science
Corp., Ergo Texas Holdings Inc., Ergo Science Development Corp., Ergo Science Inc., Ergo Science
Holdings, Inc., Pliva and the Board of Supervisors of
Louisiana State University and Agricultural and Mechanical College, and each of their
respective Affiliates and permitted successors and assigns.

     1.85 “Trade Forecast” means the Volume Forecast for trade demand, not including
Samples.

     1.86 “United States Bankruptcy Code” means the U.S. Bankruptcy Code, 11 U.S.C. §§ 101,
et seq.

     1.87 “Upstream Agreements” means (a) the S2/Vero Agreement; and (b) the agreements by
and between VeroScience and each of the Third Party Rights Holders under

8

 

which such Persons are entitled to any payment as a result of sales of the Product, as set forth on
Schedule 1.87 hereto.

     1.88 “VeroScience” has the meaning set forth in the preamble to this Agreement.

     1.89 “VeroScience Financials” has the meaning set forth in Section 9.2(i).

     1.90 “VeroScience Information” means any and all know-how and information, trade
secrets, pre-clinical and clinical development, including VeroScience’s Proprietary Information,
and other technical information including any of the foregoing generated under or in connection
with this Agreement or the S2/Vero Agreement (whether or not confidential, proprietary, patented or
patentable), and all tangible embodiments of any of the foregoing in written, electronic or any
other form, that are necessary or reasonably useful, in the ordinary course of business, for
Manufacturing or Commercializing the Product that is owned, Controlled, used or held by VeroScience
and associated trade secrets and other know-how, that in all cases are reasonably useful or are
required for the Commercialization and Manufacture of the Product; provided, that VeroScience
Information shall not include information that S2 or VeroScience are under an obligation to
unrelated Third Parties not to disclose.

     1.91 “VeroScience IP” means the VeroScience Patents, the VeroScience Information and
the Product Trademarks.

     1.92 “VeroScience Patents” means the Patents set forth on Schedule 1.92 and
any other Patents owned, Controlled, used or held by VeroScience at any time during the Term that
cover the composition of matter or method of manufacture or use of the Product.

     1.93 “Volume Forecast” means a non-binding forecast of the anticipated demand for
trade Product for a [***] ([***])- month period, as delivered and updated in accordance with
Article VI.

     1.94 “Websites” has the meaning set forth in Section 4.9.

ARTICLE II

GRANT OF RIGHTS; DEVELOPMENT

     2.1 Grant of Rights 

     (a) During the Term, subject to the terms and conditions of this Agreement, S2
hereby grants to Santarus and its Affiliates and Santarus and its Affiliates hereby
accept an exclusive (subject to Section 2.1(b)) sublicense and right to make, have
made, use, have used, offer to sell, sell, have sold, import, have imported and to
otherwise Commercialize, but not to Develop, except as set forth herein, the Product
under the Product Trademarks under the VeroScience IP in the Field in the Territory,
including the right to record sales for its own account. For the avoidance of doubt,
the writing of a prescription by a Third Party in the Territory for the Product
outside the Field in and of itself shall not constitute a breach of this Agreement by
Santarus. Each of S2 and VeroScience agrees that neither of them nor their respective
Affiliates shall have

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

9

 

any right to Commercialize or Manufacture the Product in the Territory during the Term for
sale, distribution or use in the Territory, except as set forth in this Section 2.1.

     (b) Notwithstanding Section 2.1(a), during the Term, subject to the terms and conditions of
this Agreement, (i) S2 reserves for itself and its sublicensees or appointees the right to Promote
the Product under the Product Trademarks in portions of the Territory where Santarus is not
actively Promoting the Product using S2’s own sales representatives and at its sole cost and
expense (the “S2 Co-Promotion Right”) and (ii) S2 reserves for itself and for VeroScience
and for their sublicensees or appointees the right to make, have made, export, have exported and to
otherwise Manufacture the Product under the VeroScience IP in the Territory, in each case, for
Commercialization outside the Territory. S2 must provide Santarus with at least [***] ([***]) days
prior written notice of its intent to exercise the S2 Co-Promotion Right and must reasonably
coordinate its activities with Santarus (including using the Promotional Materials and sales force
messaging that Santarus is using in its Commercialization efforts hereunder) so as not to
materially and adversely impact Santarus’ Commercialization hereunder. Except as provided under
this Section 2.1(b), to the extent permitted by Legal Requirements, neither S2 nor VeroScience
shall, nor shall cause its Affiliates, sublicensees and distributors to, knowingly or intentionally
sell the Product into the Territory, and should S2 or VeroScience become aware of any such Product
diversion, such party shall, and shall cause its Affiliates, sublicensees or distributors to, as
applicable, use Commercially Reasonable Efforts to stop such diversion. To the extent permitted by
Legal Requirements, S2, VeroScience and/or their respective Affiliates shall include in agreements
with sublicensees and distributors that sell the Product covenants from such sublicensees and
distributors to not knowingly or intentionally sell Products in the Territory. For the avoidance of
doubt, all sales of the Product in the Territory generated following S2’s exercise of the S2
Co-Promotion Right shall continue to be recognized as sales by Santarus and shall be included in
the calculation of the Product Royalty under Section 7.1(b).

     (c) All rights and licenses granted under or pursuant to this Agreement, including amendments
hereto, are, for all purposes of 11 U.S.C. § 365(n), licenses of rights to intellectual property as
defined in the United States Bankruptcy Code. Each party may elect to retain and may fully exercise
all of its rights and elections under 11 U.S.C. § 365(n).

     2.2 Sublicense Rights

     Santarus shall have the right, without S2’s or VeroScience’s prior consent, to delegate rights
and obligations hereunder to an Affiliate and to appoint Affiliates to
Manufacture or Commercialize the Product in the Territory. Furthermore, Santarus shall have
the right to appoint any Third Party designee(s) to Manufacture or Commercialize the Product in the
Territory alone or in combination with Santarus or its Affiliates and/or to sublicense the rights
granted to it under Section 2.1; provided, that any sublicense of the rights granted to it under
Section 2.1 shall require the prior consent of VeroScience, not to be unreasonably conditioned,
withheld or delayed; provided, further, in the event of any sublicense or delegation of rights by
Santarus hereunder, (i) such sublicense or delegation shall contain terms and conditions which are
consistent with the terms and conditions of this Agreement and the Upstream Agreements, (ii) such
sublicense or delegation shall be subject and subordinate to the terms and conditions of

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

10

 

this Agreement, (iii) the sublicense or delegation by Santarus hereunder shall not relieve
Santarus of its obligations under the Agreement, (iv) Santarus shall ensure that each of its
sublicensees and designees accepts and complies with all applicable terms and conditions of this
Agreement and (v) Santarus shall remain responsible for the performance or nonperformance of any
such sublicensee or delegee hereunder. Where otherwise applicable, each sublicense by Santarus
shall fully comply with Article II, Paragraph (D) of the LSU License (as defined in Schedule
1.87).

     2.3 Exclusivity

     During the Restricted Term, neither VeroScience, nor S2 nor any of their respective
Affiliates, shall (a) directly or indirectly, including by sublicense or assignment of rights,
Manufacture or Commercialize the Product or otherwise use the Product Trademarks other than the
trade name “VeroScience” (except as set forth in this Agreement, including as permitted under
Section 2.1(b), under Schedule 2.4(b) or in connection with Development of the Product including
the Post Approval Commitments), or (b) grant any rights or licenses to any Third Party to
Manufacture or Commercialize the Product or otherwise use the Product Trademarks (except as set
forth in this Agreement, including as permitted under Section 2.1(b)), in the case of each of (a)
and (b) above, in the Territory.

     2.4 Limitation on Bromocriptine Activities 

     (a) Santarus shall not, directly or indirectly, manufacture, promote, market or distribute, or
grant a license or sublicense to any Third Party enabling such Third Party to, directly or
indirectly, manufacture, promote, market or distribute, any product containing bromocriptine or
bromocriptine mesylate as an active ingredient in the Territory during the period commencing on the
Effective Date and ending upon the earlier of twelve (12) months following the end of the Term or
the first commercial sale of a Generic Product in the Territory, other than the Product or any
Included Additional Products.

     (b) Neither S2 nor VeroScience shall, directly or indirectly, promote, market or distribute,
or grant a license or sublicense to any Third Party enabling such Third Party to, directly or
indirectly, promote, market or distribute, any product containing bromocriptine or bromocriptine
mesylate as an active ingredient in the Territory for the treatment of type 2 diabetes in humans
(the “Field”) or the same indication as an Included Additional Product (as stated in the
applicable package insert or as stated in the Development plan for such Included Additional
Product) during the period commencing on the Effective Date and ending upon the earlier of the end
of the Term or the first commercial sale of a Generic Product in the Territory (the “Restricted
Term”), other than
(A) as set forth in Section 2.1(b), (B) as set forth on Schedule 2.4(b), or (C) with
respect to any Excluded Additional Products.

     2.5 Post-Approval Commitments and Development of Additional Products 

     (a) The parties acknowledge that VeroScience has committed with the FDA to conduct certain
development activities with respect to the Product as further described on Schedule 2.5(a)
(the “Post-Approval Commitments”). Subject to the monitoring of the JSC in

11

 

accordance with Article III, VeroScience shall complete such Post-Approval Commitments, at the cost
and expense of S2 and VeroScience, in a timely manner and in compliance with all applicable Legal
Requirements; provided, Santarus has supplied VeroScience with sufficient quantities of Product
reasonably necessary for Post-Approval Commitments pursuant to Section 6.1. [***] VeroScience shall
be responsible, at the cost and expense of S2 and VeroScience, for any other Development associated
with the Product. Subject to the exclusions set forth in Section 1.61, all data and information
derived from Post-Approval Commitments and Development activities of VeroScience relating to the
Product or Additional Products shall be deemed to be Proprietary Information of VeroScience for all
purposes hereunder; provided, however, that Santarus may use such data and information, in the
exercise of, and to the extent of, its rights hereunder.

     (b) At any time after the [***] ([***]) anniversary of the Effective Date, any of Santarus,
VeroScience and S2 may initiate good faith discussions among the parties regarding additional
Development activities to be undertaken in support of (1) delivery and/or formulation modifications
to the Product for the treatment of type 2 diabetes in humans, (2) a combination product which
contains bromocriptine mesylate as an active pharmaceutical ingredient for the treatment of type 2
diabetes in humans, or (3) obtaining Regulatory Approval of the Product for any indication other
than the treatment of type 2 diabetes in humans, in each case, as to which a new “new drug
application” (as such term is used under the Act) or supplement to NDA No. 20,866 would be required
prior to marketing or selling of such product (collectively, “Additional Product(s)”);
[***]. Subject to the confidentiality provisions of this Agreement, during the [***] period
following each initiation of such discussions pursuant to this Section 2.5(b), VeroScience shall
provide to Santarus and S2 such information regarding any such Development activities or Additional
Product(s) as is reasonably requested by Santarus or S2 or as would reasonably be expected to be
material to Santarus’s decision regarding participation in and/or the provision of financial
support for Development associated with such Additional Product(s), in each case, to the extent
VeroScience possesses such information and is not prohibited from disclosing such information under
the terms of an applicable Third Party agreement. In the event that Santarus, VeroScience and S2
agree on terms under which Santarus will participate in and/or provide financial support for
Development associated with an Additional Product during the applicable [***] period, Santarus
shall be granted rights to such Additional Product on terms and conditions mutually agreed by the
parties. The obligations of the parties with respect to the Development of such Additional Product
and the rights of Santarus to such Additional Product shall be set forth in an amendment to this
Agreement or a separate agreement, as mutually agreed by the parties; provided, that all
Development rights with respect to such Additional Products will remain with VeroScience. Following
the execution and delivery of any such amendment or separate agreement, such Additional Product
shall be deemed to be an “Included Additional Product” for all purposes hereunder. In the
event that Santarus, VeroScience and S2 do not agree on terms under which Santarus will participate
in and/or provide financial support for Development associated with an Additional Product during
the applicable [***] period (any such Additional Product(s),
an “Excluded Additional Product”), then (i) VeroScience and S2 may agree on their own,
or enter into an agreement with a Third Party with respect to the Development of, and/or to
Commercialize, such Excluded Additional Product(s) and (ii) Santarus shall have no further rights
with respect to such Excluded Additional Product(s); provided, that if S2 and/or

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

12

 

VeroScience enter into any such agreement with a Third Party within [***] following the
initiation of discussions related to such Excluded Additional Product pursuant to this Section
2.5(b), (a) the terms of any such Third Party agreement shall not be materially less favorable to
VeroScience and/or S2, taken as a whole, than the terms most recently proposed by Santarus; and (b)
in connection with any such Third Party agreement, such Third Party shall not receive any material
information, in connection with its consideration of such Excluded Additional Product, related to
the Excluded Additional Product, which was available but not provided to Santarus during the
applicable [***] period; provided, further, that VeroScience and S2 have followed the procedure set
forth in this Section 2.5(b)). [***].

     (c) The rights and obligations of the parties under Section 2.5(b) shall terminate upon the
earlier of (1) the end of the Term or (2) the first commercial sale of a Generic Product in the
Territory.

     (d) For purposes of this Agreement, “Development” means, with respect to the Product
or an Additional Product, as applicable, all non-clinical, pre-clinical and clinical drug
development activities reasonably relating to the discovery and development of the Product or such
Additional Product, as applicable, and submission of information to a Governmental Authority.
Development shall include toxicology, pharmacology, and other non-clinical and pre-clinical
efforts, test method development and stability testing, manufacturing process development,
formulation development, delivery system development, quality assurance and quality control
development, statistical analysis, clinical studies and activities relating to obtaining Regulatory
Approval for the Product or such Additional Product, as applicable.

     2.6 S2/Vero Agreement 

     (a) The parties acknowledge that certain of the terms and conditions of this Agreement may be
inconsistent with the S2/Vero Agreement. To the extent of any such inconsistency, the parties shall
negotiate in a good faith and attempt to resolve such inconsistency; provided, that any such
resolution shall preserve the rights of the parties under this Agreement. [***].

     (b) VeroScience hereby waives the requirements of subsection (a) of Section 3.2 of the S2/Vero
Agreement, acknowledges compliance with subsections (b), (c) and (e) of Section 3.2 of the S2/Vero
Agreement and agrees that the relevant provision of this Agreement supersedes subsection (d) of
Section 3.2 of the S2/Vero Agreement.

     (c) Without limiting S2 or VeroScience’s rights under Section 2.1(b), during the Term, S2
hereby agrees to forbear from taking any action under the S2/Vero Agreement to the extent such
action would conflict with the rights granted to Santarus under this Agreement or would otherwise
reasonably be expected to result in a material adverse effect on Commercialization in the Territory
hereunder (it being agreed that nothing in this Section 2.6 precludes S2 or VeroScience from
conducting Development, Manufacturing and Commercialization of the Product or Additional Products
outside the Territory), including commencing a legal action in equity or at law, seeking to enforce
any right or obligation that S2

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

13

 

may have under the S2/Vero Agreement, including the license rights granted to S2 thereunder with
respect to Bromocriptine (as defined therein), to the extent such rights or obligations would
conflict with the rights granted to Santarus under this Agreement.

     (d) [***].

     (e) [***].

     (f) [***].

     (g) In the event that the S2/Vero Agreement expires or is terminated during the Term, Santarus
and VeroScience shall continue under this Agreement, and, to the extent necessary, shall put into
place appropriate amendments hereto, in form and substance reasonably agreed by Santarus and
VeroScience, consistent with the then-existing rights and obligations of Santarus hereunder;
provided, however, that in no event shall Santarus be required to assume any of S2’s obligations to
VeroScience under the S2/Vero Agreement (to the extent such obligations are broader than Santarus’
obligations under this Agreement).

     2.7 Retention of Rights 

     Except as expressly set forth herein, nothing contained herein shall be deemed to grant
Santarus, by implication or otherwise, a license, sublicense or other right or interest in any
Patent, trademark or other similar property of S2, VeroScience or their respective Affiliates.
Except as expressly set forth herein, nothing contained herein shall be deemed to grant S2 or
VeroScience, by implication or otherwise, a license, sublicense or other right or interest in any
Patent, trademark or other similar property of Santarus or its Affiliates. Except as expressly set
forth herein or in any amendment to this Agreement entered into following the Effective Date in
accordance with Section 2.5(b), nothing contained herein shall be deemed to grant Santarus, by
implication or otherwise, a license, sublicense or other right or interest in or with respect to
any Additional Product.

     2.8 Assignment of Patheon Agreements

     Effective as of the Effective Date, S2 hereby assigns to Santarus and Santarus hereby assumes
the Patheon Agreement and the Supplemental Patheon Agreements,
including all of S2’s rights and obligations thereunder (other than obligations accrued prior
to the Effective Date, except for those obligations described on Schedule 2.8, which, subject to
Section 7.1(c), shall be assumed by Santarus). Each of Santarus, S2 and VeroScience acknowledge
that, as of the Effective Date, (i) there is no existing agreement providing for the supply of
active pharmaceutical ingredient for the Product in the Territory and that the active
pharmaceutical ingredient has been ordered using purchase orders on an as-needed basis; and (ii)
the Patheon Agreement and the Supplemental Patheon Agreements are the only existing Supply
Agreements.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

14

 

ARTICLE III

GOVERNANCE

     3.1 Joint Steering Committee

     (a) Establishment. The parties agree to establish, for the purposes specified herein,
a Joint Steering Committee (the “JSC”). The parties acknowledge and agree that the JSC does
not have the power to amend, modify or waive any of the terms or conditions of this Agreement.

     (b) Membership. The JSC shall be established by the parties and shall be comprised of
four (4) members, one (1) of whom shall be appointed by VeroScience, one (1) of whom shall be
appointed by S2 and two (2) of whom shall be appointed by Santarus. Each party’s initial
appointments to the JSC are set forth on Schedule 3.1(b). A party may change any of its
representatives at any time if a new person is appointed to any of the foregoing positions by
giving written notice to the other parties. The total number of JSC members may be changed by
unanimous vote of the JSC from time to time as appropriate; provided, that the JSC shall in all
cases be comprised of an equal number of members from each of VeroScience and S2, on the one hand,
and Santarus, on the other hand. Each party shall designate one (1) representative to serve as
co-chairs of the JSC (the “Co-Chairs”). The members appointed to the JSC by each party
shall be officers or employees of such party and shall be vested with appropriate decision-making
authority and power by such party.

     (c) JSC Responsibilities. Except as otherwise set forth herein, the JSC shall provide
strategic input and serve as a forum for monitoring the Post-Approval Commitments and Development
and Commercialization. The responsibilities of the JSC shall be exercised consistent with this
Agreement and shall consist of the following:

               (i) monitoring any Post-Approval Commitments;

               (ii) monitoring any proposed Development activities associated with the Product;

               (iii) monitoring Commercialization of the Product in the Territory;

               (iv) monitoring Manufacturing of the Product in the Territory;

               (v) if (and only if) the parties reach mutual agreement with respect to
Development and Commercialization of Included Additional Products pursuant to Section
2.5(b), monitoring any proposed Development associated with such Included Additional
Products and monitoring the Commercialization associated with such Included
Additional Products;

               (vi) acting as a forum for regular updates on the activities over which it has
monitoring responsibility; and

15

 

               (vii) such other functions pertaining to Post-Approval Commitments, Development or
Commercialization as may be mutually agreed upon by the parties from time to time.

     (d) Meetings of the JSC. Meetings of the JSC may be called by the Co-Chairs of the JSC
from time to time and, upon no less than ten (10) days’ notice, shall otherwise be called when
requested by a party; provided, however, that meetings of the JSC shall be held at least once every
four (4) Agreement Months. If possible, the meetings shall be held in person or where appropriate,
by video or telephone conference. Unless otherwise agreed, the location of any in-person meetings
of the JSC shall alternate among the corporate offices of the parties. The parties shall determine
the form of the meetings. Subject to appropriate confidentiality undertakings where applicable,
each party shall have the right, upon written notice to the other parties, to have present at JSC
meetings additional, non-voting participants (not to exceed ten (10) such participants at any JSC
meeting without the consent of the other parties). Such additional participants shall not be deemed
to be, or have any rights or responsibilities of, a member of the JSC. The parties shall cause
their respective representatives on the JSC to use their reasonable efforts to resolve all matters
presented to them as expeditiously as possible. The party hosting any meeting shall propose the
agenda for the meeting and appoint a secretary to the meeting who shall record the minutes of the
meeting. Such minutes shall be circulated to the parties promptly following the meeting for review
and comment and for unanimous ratification by both parties. Each party shall bear its own travel
and related costs incurred in connection with participation in the JSC.

     3.2 Responsibilities of the Parties with Respect to the Product in the Territory.

     Unless otherwise expressly set forth herein, (i) VeroScience shall have final decision-making
authority with respect to all matters directly relating to Post-Approval Commitments, the
Development of the Product and Additional Products, and regulatory matters (including Regulatory
Approvals); and (ii) Santarus shall have final decision-making authority with respect to all other
matters directly relating to Manufacturing the Product in the Territory for Commercialization in
the Territory and Commercialization of the Product in the Territory, in each case, with respect to
all matters brought before the JSC related thereto, or otherwise. In each instance, a party shall
consider in good faith any suggestions or input received from any other party with respect to its
area of final decision-making authority. Notwithstanding the foregoing, the parties will reasonably
cooperate on regulatory matters to the extent relating to Manufacturing and Commercialization.

ARTICLE IV

COMMERCIALIZATION

     4.1 Commercialization

     (a) Subject to applicable Legal Requirements, as well as the provisions of this Agreement,
Santarus shall use Commercially Reasonable Efforts to Commercialize in the

16

 

Territory. Santarus shall initiate its Commercialization activities on or before the Promotion
Commencement Date.

     (b) Santarus shall have access, free of charge, to clinical and non-clinical data to the
extent directly related to the Product generated by or on behalf of and controlled by S2 or
VeroScience, whether before or after the Effective Date, solely for use in its Commercialization or
related medical education or publication activities. All uses by Santarus of such clinical or
non-clinical data shall be governed by the confidentiality obligations of this Agreement. For the
avoidance of doubt, neither S2 nor VeroScience shall have any obligation under this Section 4.1(b)
with respect to data generated for or with respect to Additional Products except as provided in
Section 2.5(b) or with respect to data not directly related to the Product or an Included
Additional Product.

     (c) For the avoidance of doubt, the obligations of Santarus as set forth in Section 4.1(a)
shall be suspended for any period of time during which: (i) VeroScience is unable to maintain the
continued effectiveness of Regulatory Approvals in the Territory which has the effect of preventing
Santarus from performing its obligations under this Agreement, or (ii) either S2 or VeroScience has
failed to perform any obligation under this Agreement or the S2/Vero Agreement which has the effect
of preventing Santarus from initiating by the Promotion Commencement Date or continuing its
Commercialization of the Product.

     4.2 Representations to Customers

     None of VeroScience, S2 or Santarus will make any false or misleading representations to
Professionals, customers or others regarding the Product nor will any party make any
representations, warranties or guarantees with respect to the specifications, features or
capabilities of the Product that are not consistent with the applicable then-current FDA approved
labeling and package insert (except to the extent permitted by Legal Requirements).

     4.3 Staffing; Training

     Santarus shall be solely responsible for all costs and expenses of compensating the Santarus
Sales Force. Santarus will develop training materials for the Santarus Sales Force with respect to
the Product. Santarus will provide each of S2 and VeroScience with the opportunity to review key
training materials related to the Product and prepared by Santarus by delivering copies of such
training materials to S2 and VeroScience. S2 and VeroScience shall have [***] ([***]) business days
after their receipt of the training materials to provide comments on such training materials, which
Santarus shall reasonably consider in good faith to ensure that such training materials are not
inconsistent with the scientific and medical information for the Product. Promptly after the
Effective Date, S2 shall provide to Santarus copies of any training materials in its possession and
shall provide reasonable assistance from time to time with Santarus’ efforts to develop training
materials.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

17

 

     4.4 Promotional Materials; Educational Materials

     Santarus shall, at its own expense, have the right to create, develop, produce or otherwise
obtain, and utilize sales, promotional, advertising, marketing, educational and training materials
(“Promotional Materials”) to support its Commercialization activities. Santarus will
provide each of S2 and VeroScience with the opportunity to review key Promotional Materials,
including key messaging, before distribution to Third Parties by delivering copies of such
Promotional Materials to S2 and VeroScience. S2 and VeroScience shall have [***] ([***]) business
days after their receipt of the Promotional Materials to provide comments on such Promotional
Materials, which Santarus shall reasonably consider in good faith to ensure that such Promotional
Materials are not inconsistent with the scientific and medical information for the Product.
Santarus shall provide S2 and VeroScience with copies of representative samples of all final
Promotional Materials, and shall provide to VeroScience the requisite number of copies of
Promotional Materials in final printed form in a timely manner so as to allow VeroScience to
satisfy its obligation to timely file such materials with the FDA, and VeroScience will make or
cause to be made such filing with the FDA within [***] ([***]) business days of its receipt of such
copies. Notwithstanding the foregoing, the parties shall discuss in good faith the establishment of
a process for Santarus to assist VeroScience with such FDA filings and/or to make such filings on
VeroScience’s behalf.

     4.5 Annual Commercialization Plan

     On or prior to [***] of the preceding calendar year with respect to each calendar year during
the Term beginning with the 2011 calendar year, Santarus shall provide to S2 and VeroScience an
annual Commercialization plan describing its planned activities during such calendar year (the
“Annual Plan”). For clarity, the first Annual Plan deliverable hereunder (with respect to
the 2011 calendar year) shall be delivered to S2 and VeroScience on or prior to [***] and shall
include at least the activities set forth on Schedule 4.5. Santarus will provide each of S2
and VeroScience with a timely opportunity to review, discuss and provide comments on each Annual
Plan and with a timely opportunity (as set forth below) to review, discuss and provide comments on
material modifications thereto. The Annual Plan may be modified from time to time as Santarus
reasonably deems appropriate, subject to (i) Santarus’ compliance with its obligations under this
Agreement, (ii) reasonably prompt notice to S2 and VeroScience of any material modifications to the
Annual Plan that would reasonably be expected to have a material adverse effect on Net Sales, and
(iii) notice to S2 and VeroScience of any other material modifications at the next JSC meeting.

     4.6 Reports and Updates

     (a) During the Launch Period, within [***] ([***]) business days following the end of each
Agreement Month during the Launch Period, Santarus shall provide S2 and VeroScience with a status
report, which report will summarize Santarus’ Commercialization activities pursuant to this
Agreement for such prior Agreement Month.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

18

 

     (b) Following the Launch Period, within [***] ([***]) days following the end of each Agreement
Quarter, Santarus shall provide S2 and VeroScience with a status report, which report will
summarize Santarus’ Commercialization activities pursuant to this Agreement for such prior
Agreement Quarter.

     (c) Without limiting the foregoing, within [***], Santarus shall provide S2 and VeroScience,
to the extent available at no cost or purchased by Santarus and subject to timely receipt by
Santarus, a summary report relating to Prescription Data for such prior week, or Agreement Month,
as applicable. For clarity, the data provided pursuant to this Section 4.6(c) shall not consist of
individual prescriber-level data nor shall any data be required to be provided hereunder to the
extent Santarus is not permitted to share data under the applicable Third Party contract for such
data and it would require the payment of additional fees to the Third Party provider of such data,
unless S2 agrees to pay such additional fees.

     (d) Without limiting the foregoing or anything contained in Article III, upon the reasonable
request of S2 or VeroScience, Santarus shall provide further periodic updates to S2 and VeroScience
during the Term regarding its Commercialization strategy and material Commercialization activities
in the Territory (including with respect to pre-marketing activities, market research and launch
plans), which periodic updates may include such information as previously provided to the JSC or
otherwise provided under this Section 4.6. Santarus will reasonably consider S2 and VeroScience
input on activities taken or to be taken by Santarus hereunder. Santarus will have final
decision-making authority relating to such
Commercialization strategy as well as tactical implementation of such strategy.

     (e) Subject to the exclusions set forth in Section 1.61, all data and information derived from
Commercialization activities of Santarus, including any Promotional Materials or reports provided
hereunder except to the extent any Vero Information is included or incorporated therein, shall be
deemed to be Proprietary Information of Santarus for all purposes hereunder; provided, that to the
extent Santarus is not prohibited from disclosing such information under the terms of an applicable
Third Party agreement binding on Santarus, S2 and VeroScience shall not be prohibited under this
Section 4.6(e) from using such Proprietary Information in connection with developing a global
branding strategy for the Product or an Included Additional Product, as applicable, outside the
Territory or in Commercializing the Product or an Included Additional Product, as applicable, in
the Territory following the expiration or termination of this Agreement.

     4.7 Medical Inquiries

     The parties acknowledge that each may receive requests for medical information concerning the
Product from members of the medical and paramedical professions and consumers regarding the
Product. If such requests are received by Santarus or S2, the request will be referred to
VeroScience’s medical department. VeroScience shall also be responsible for responding to such
requests that are received by S2 or VeroScience, all of
which responses shall be in compliance with all applicable Legal Requirements and the NDA.
VeroScience shall promptly provide Santarus with (i) copies of all written materials and (ii)
written summaries of all oral advice, provided by VeroScience in response to such inquiries.
VeroScience and S2 shall

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

19

 

be obligated for any costs associated with VeroScience’s responsibilities pursuant to this Section
4.7. In the event that VeroScience fails to perform its obligations under this Section 4.7,
Santarus shall have a step-in right to perform such obligations in collaboration with and on behalf
of VeroScience and in accordance with all applicable Legal Requirements and the NDA, and Santarus
shall deduct its reasonable out-of-pocket costs for performing such obligations from the Product
Royalty payable under Section 7.1(b).

     4.8 Trademarks

     To the extent reasonably practicable, all Promotional Materials that make reference to the
Product shall include the Product Trademarks. All uses of the Product Trademarks by Santarus (or
any of its Affiliates, licensees, sublicenses, subcontractors or assigns) to identify or in
connection with the Commercialization in the Territory shall be in accordance with applicable Legal
Requirements and all reasonable trademark usage guidelines of VeroScience as set forth on
Schedule 4.8. Subject to this Section 4.8 and to applicable Legal Requirements, Santarus
shall have the right to use the Santarus Trademarks, and include the name “Santarus” or any
variation thereof on the Promotional Materials. Santarus recognizes VeroScience’s right and title
to the Product Trademarks, and shall not at any time, during or after the Term, do or knowingly
suffer to be done any act or thing which will in any way impair the rights of VeroScience in or to
the Product Trademarks. Santarus acknowledges and agrees that it shall not acquire and shall not
claim any title to the Product Trademarks adverse to VeroScience by virtue of the rights granted
under this Agreement or through Santarus’ use of the Product Trademarks, it being the intention of
the parties that all goodwill and improved reputation generated by Santarus and use of the Product
Trademarks shall inure to the benefit of the owner of such Product Trademarks.

     4.9 Product Websites

     Santarus shall have the right to establish and maintain websites for the Product aimed at
users of the Product in the Territory, including use of the domain name “cycloset.com”
(“Websites”), and develop content for the Websites. Santarus will provide each of S2 and
VeroScience with the opportunity to review key content for the Websites related to the Product and
prepared by Santarus by delivering copies of such content to S2 and VeroScience. S2 and VeroScience
shall have [***] ([***]) business days after their receipt of the content for the Websites to
provide comments on such content, which Santarus shall reasonably consider in good faith to ensure
that such content is not inconsistent with the scientific and medical information for the Product.
If requested by S2 or VeroScience, Santarus, S2 and VeroScience shall reasonably cooperate to add
links or other appropriate functionality to the Websites maintained by Santarus aimed at users of
the Product outside the Territory.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

20

 

ARTICLE V

REGULATORY AFFAIRS

     5.1 Regulatory Approvals

     VeroScience shall maintain and continue all Regulatory Approvals currently in effect for the
Product. Santarus agrees that all Regulatory Approvals and applications therefor with respect to
the Product in the Territory shall be in the name of, and shall be owned by, VeroScience.

     5.2 Compliance with Regulatory Requirements

     Unless otherwise required by Legal Requirements or expressly required by this Agreement,
VeroScience will retain exclusive authority over and responsibility for (including responsibility
with S2 for all costs and expenses associated with) complying with all regulatory requirements with
respect to the Product in the Territory which arise as a result of VeroScience’s status as the
holder of the NDA, including (a) maintaining and updating of the NDA as reasonably necessary to
market and sell the Product in the Territory, (b) the development and submission of applications
for new formulations, dosage strengths or indications of the Product in the Territory (it being
agreed than neither S2 nor VeroScience shall have any obligation to develop or submit any such
application), (c) the reporting of any Adverse Drug Experiences to the FDA, and (d) the filing of
Promotional Materials with the FDA.

     5.3 Compliance

     (a) In performing its duties hereunder, each party shall, and shall cause its employees,
agents and subcontractors to, comply with all Legal Requirements, including the FDA’s regulations
and guidelines concerning the advertising of prescription drug products, DDMAC’s promotional
guidelines, the PhRMA Code on Interactions with Healthcare Providers, the Prescription Drug
Marketing Act of 1987, as amended, and the rules and regulations promulgated thereunder, equal
employment, non-discrimination and federal and state anti-kickback Legal Requirements, and Legal
Requirements with respect to submission of false claims to governmental or private health care
payors, which may be applicable to the activities to be performed by such party hereunder. None of
Santarus, S2, VeroScience and any party’s employees, agents or subcontractors shall offer, pay,
solicit or receive any remuneration to or from Professionals in order to induce referrals of or
purchase of the Product in violation of applicable Legal Requirements, including without limitation
federal or state anti-kickback Legal Requirements.

     (b) Sales Force Training.

               (i) Santarus hereby represents, warrants and covenants that the Santarus Sales Force shall
have been trained in compliance with applicable Legal Requirements prior to engaging in Promotion
of the Product.

21

 

               (ii) S2 hereby represents, warrants and covenants that any sales representatives utilized by
S2 in accordance with Section 2.1(b) shall have been trained in compliance with applicable Legal
Requirements prior to engaging in Promotion of the Product.

     5.4 Communications with Governmental Authorities

     Except to the extent set forth in this Section 5.4, VeroScience shall be responsible for
communications with the FDA concerning the Product. VeroScience shall (a) as soon as practicable,
but in any event, within [***] ([***]) business days, provide each of S2 and Santarus with copies
of all such material communications to or from the FDA (including summaries of all such verbal
communications) to the extent related to the Product (except that routine communications as to such
matters (e.g., FDA 2253 correspondence) may be forwarded to each other party within [***] [***])
business days) and (b) reasonably respond to all inquiries by each other party relating thereto.
VeroScience will reasonably consult with each other party concerning material communications with
the FDA or other Governmental Authorities to the extent relating to the Product, including
providing each other party with a copy of all draft responses related to such matters as soon as
practicable and considering in good faith any comments provided to VeroScience by any other party.
For clarity, during the Term, Santarus shall have the right to communicate with (i) the FDA if
required by Legal Requirements, with advance notice to VeroScience, to the extent reasonably
practicable, or (ii) any other Governmental Authority regarding the Product if such communication
is necessary to comply with the terms of this Agreement or any Legal Requirement (including without
limitation state or local Legal Requirements related to marketing activities undertaken by Santarus
or the Santarus Sales Force). Santarus shall have the right to attend and participate in all
meetings between VeroScience and the FDA pertaining to the Product in the Territory to the extent
permitted under applicable Legal Requirements.

     5.5 Product Complaints

     Santarus shall maintain a customer service call center (either itself or through a Third Party
provider), at Santarus’s cost and expense, to handle initial intake of Product Complaints or other
inquiries. Any calls relating to medical matters will be provided to the call center maintained by
VeroScience pursuant to Section 5.6(a). Santarus and VeroScience shall reasonably cooperate to
establish procedures pursuant to which each of Santarus and VeroScience will receive prompt
notification of Product Complaints within [***] ([***]) days of its receipt thereof; provided, that
all complaints concerning suspected or actual Product tampering, contamination or mix-up shall be
delivered within [***] ([***]) hours of its receipt thereof. Santarus and VeroScience will work
together to determine appropriate corrective and other actions with regard to Product Complaints,
with VeroScience being responsible for Product Complaints involving Adverse Drug Experience Reports
in accordance with Section 5.6 and Santarus being responsible for Manufacturing related Product
Complaints.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

22

 

     5.6 Adverse Drug Experience Reports

     (a) VeroScience shall maintain a medical information call center (either itself or through a
Third Party provider), at the sole cost and expense of S2 and VeroScience, to handle Adverse Drug
Experience Reports and Serious Adverse Drug Experience Reports.

     (b) Each party shall notify each other party: (i) of all Serious Adverse Drug Experience
Reports within [***] ([***]) hours of the time such Serious Adverse Drug Experience Report becomes
known to such party (including its employees); and (ii) of all Adverse Drug Experience Reports
within [***] ([***]) days of the time such Adverse Drug Experience Report becomes known to such
party (including its employees).

     (c) Except as may otherwise be required by Legal Requirements, (i) Santarus shall not disclose
any information concerning Adverse Drug Experience Reports or Serious Adverse Drug Experience
Reports to any Person or Governmental Authority (other than the parties) without the prior consent
of VeroScience; and (ii) as among the parties, VeroScience shall have the sole discretion to
determine whether any Product Complaint, Adverse Drug Experience Report or Serious Adverse Drug
Experience Report must be reported to the FDA or any other Governmental Authority.

     (d) All follow-up investigations concerning Adverse Drug Experience Reports and Serious
Adverse Drug Experience Reports shall be conducted by VeroScience; provided, that Santarus shall
have the right to participate in such investigations upon its reasonable request.

     (e) Santarus and VeroScience will enter into a separate and more detailed pharmacovigilance
agreement, consistent with the terms of this Agreement, within thirty (30) days following the
Effective Date.

     5.7 Recalls or Other Corrective Action

     As among the parties, Santarus and VeroScience shall have responsibility for and shall
mutually agree on all decisions with respect to any recall (including recall of packaging and
Promotional Materials), market withdrawals or any other corrective action related to the Product in
the Territory; provided, that either Santarus or VeroScience may initiate a recall due to bona fide
safety or efficacy concerns. Santarus and VeroScience shall promptly consult with one another with
respect to any such actions proposed to be taken in the Territory (and in all events prior to the
taking of such actions, subject to applicable Legal Requirements), including all actions that are
reasonably likely to result in a material adverse effect on the marketability of the Product in the
Territory. Santarus and VeroScience (and through VeroScience, S2) shall equally share the
reasonable, documented, direct, out-of-pocket costs incurred in connection with participating in
such recall, market withdrawal or other corrective action. For clarity, the remedies under this
Section 5.7 shall in no event limit the rights or remedies of the parties under this Agreement,
including the right to seek damages and costs that may be available under this Agreement.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

23

 

     5.8 Assistance

     Each party agrees to provide to the other parties all reasonable assistance and take all
actions reasonably requested by another party that are necessary to enable a party to comply with
any Legal Requirement applicable to the Product in the Territory.

     5.9 Development Reports

     To the extent permitted under applicable Third Party contracts, on or before [***] of the
Term, beginning with [***], and continuing until the earlier of the end of the Term or the first
commercial sale of a Generic Product in the Territory, VeroScience shall provide Santarus and S2
with a status report, which report will summarize VeroScience’s Development of the Product, any
Included Additional Products and Post-Approval Commitment activities for the prior [***]
([***])-month period.

ARTICLE VI

MANUFACTURING AND SUPPLY; SALES; PRICING

     6.1 Supply of Product

     (a) Santarus shall use Commercially Reasonable Efforts to supply Product in established Sample
or trade packaging configurations to VeroScience for Post-Approval Commitments and additional
Development activities as agreed by the parties at Santarus’ COGS, provided, that VeroScience
provides reasonable advance notice in accordance with the forecasting and lead-time provisions set
forth in the Patheon Agreement; provided, further, that the obligations of VeroScience hereunder
with respect to Post-Approval Commitments and additional Development activities shall be subject to
the supply by Santarus of Product for such activities.

     (b) During the Term, Santarus shall use Commercially Reasonable Efforts to ensure timely
supply of the Product in the Territory to satisfy trade demand. In accordance with the provisions
of this Agreement and all applicable Legal Requirements, Santarus shall perform or cause to be
performed all Product manufacture, labeling, packaging, warehousing, distribution and return, order
entry, customer services and all other activities to supply and distribute the Product in the
Territory in order to fill orders for Product in a timely and efficient manner. Following the
Launch Period during the Term, Santarus shall maintain at least [***] ([***]) months safety stock
of Product and at least [***] ([***]) months safety stock of the active pharmaceutical ingredient
for the Product (in each case, the “Safety Stock”) to address unanticipated changes in demand or
other manufacturing needs for the Product (calculated on the basis of the then-current Sample
Forecast and Trade Forecast).

     6.2 Volume Forecasts; Wholesaler Activities

     (a) Prior to the Effective Date, the parties have agreed on the initial Trade
Forecast, which sets forth the anticipated trade demand for the
Product in the Territory for the [***] ([***]) months following the
Promotion Commencement Date. Thereafter, at least [***] ([***])

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

24

 

days prior to the beginning of each [***] ending after the Promotion Commencement Date,
Santarus shall prepare a Trade Forecast for the next [***] ([***]) Agreement Months, using its
good faith judgment of anticipated trade demand by month for such period, and shall provide such
Trade Forecast to S2 and VeroScience for review and discussion, but not approval, at the JSC.

     (b) Santarus shall promptly inform S2 and VeroScience of any back-order situations or other
situations in which wholesaler orders of the Product have not been filled or are reasonably
anticipated not to be filled (collectively, “Back Order Events”); Santarus shall be solely
responsible for establishing a remediation plan for any such Back Order Events.

     6.3 Sales; Pricing

     (a) Santarus shall book all sales of the Product in the Territory and shall be solely
responsible for establishing pricing and for entering into any contracts and other arrangements
with any Person regarding the distribution and sale of the Product in the Territory, subject to
Section 6.3(b), and provided, that Santarus may not sell the Product as part of a bundled product
without the prior consent of S2 and VeroScience, including with respect to the price of such
bundled product and the allocation of Net Sales with respect thereto. For purposes of this Section
6.3, a “bundled product” means Product that is sold together with at least one other
pharmaceutical product for a single price or discounted price, whether sold together in the same
package or merely price bundled.

     (b) The parties have agreed on initial pricing for the Product and Santarus shall be
hereafter solely responsible for pricing decisions with respect to the Product in the Territory,
provided, that Santarus shall discuss its pricing and contracting strategy in good faith with S2
and VeroScience at JSC meetings.

     6.4 Samples

     (a) Santarus may manufacture samples of the Product that are not for sale
(“Samples”) to be distributed by Santarus in connection with its Promotion of the Product and as
permitted by the rules, guidelines and policies applicable to any Professional.

     (b) Santarus shall be responsible for distributing the Samples to the Santarus Sales Force.
Santarus shall also be responsible for securing the return and appropriate disposal of and
reconciling existing Sample inventories from discontinued members of the Santarus Sales Force.

     (c) Santarus shall be solely responsible for accountability and compliance with the PDMA for
the Santarus Sales Force, and other applicable Legal Requirements relating to such Samples or the
distribution of same by the Santarus Sales Force, and shall be responsible for adherence by member
of the Santarus Sales Force to such Legal Requirements.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

25

 

     6.5 Manufacturing Matters 

     Each party shall promptly inform each other party in the event that it becomes aware of any
matters which might reasonably be expected to have an adverse impact on the ability to supply
trade Product to wholesalers or other customers within [***] ([***]) days of any specified
delivery date. Notwithstanding the generality of the foregoing, Santarus agrees to notify S2 and
VeroScience within [***] ([***]) hours after Santarus has become aware of any event or
circumstance related to the manufacture of the Product that would reasonably be expected to impact
the safety or efficacy of Product that has been released for commercial distribution or that would
reasonably be expected to cause such released Product to be adulterated or misbranded within the
meaning of the Act.

     6.6 Upstream Agreements

     The parties acknowledge that each of S2 and VeroScience is subject to certain rights and
obligations under the Upstream Agreements. S2 and VeroScience shall maintain each Upstream
Agreement in full force and effect and neither S2 nor VeroScience shall amend, terminate or cause
to be terminated any Upstream Agreement (or any other agreement to the extent relating to rights
to, or the supply or marketing of, the Product in the Territory) in a way that would reasonably be
expected to materially adversely affect the rights of Santarus hereunder without the prior written
consent of Santarus, which consent shall not to be unreasonably withheld, delayed or conditioned.
[***]

ARTICLE VII

COMPENSATION

     7.1 Fees

     (a)

               (i) Prior to the Effective Date, Santarus has advanced to S2 an amount equal to Seven Hundred
Fifty Thousand Dollars ($750,000.00) (the “Advance”).

               (ii) Within [***] ([***]) business days of the Effective Date, in partial consideration of
the rights granted to Santarus under this Agreement and to fund or reimburse S2 and VeroScience
for research and development activities with respect to the Product, Santarus shall pay to (i) S2
an additional amount equal to [***] Dollars ($[***]) (subject to Section 7.1(a)(iv) below) and
(ii) VeroScience an amount equal to [***] Dollars ($[***]) (collectively, with the Advance, the
“Initial Fee”).

               (iii) Within [***] ([***]) business days of receipt of the Initial Fee, VeroScience shall pay
the outstanding amounts due to FDA in the approximate amount of [***] Dollars ($[***]).

               (iv) Notwithstanding the foregoing subsection (a)(ii), Santarus may withhold from the portion of the
Initial Fee to be paid to S2 an amount equal to [***] ($[***])

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

26

 

until such time as the Deposit Bank is established. Within [***] ([***]) business days of the
establishment of the Deposit Bank, Santarus shall pay to the Deposit Bank to hold in the Joint
Account an amount equal to [***] ($[***]), which VeroScience and S2 shall instruct the Deposit
Bank to pay out to satisfy their obligations under Section 4.7, Section 7.4 and Article V of this
Agreement, including, without limitation, amounts due and owing with respect to Third Party costs
and expenses associated with pharmacovigilance, medical affairs and Adverse Drug Experience
reporting, annual reports filed in connection with the NDA and user fees and establishment fees
associated with the NDA (“Regulatory Amounts”) that will are incurred from the Effective Date
through December 31, 2010 or are incurred by S2 or VeroScience as of the Effective Date.

     (b) Subject to Section 11.1(b), in partial consideration of the rights granted to Santarus
under this Agreement, Santarus shall pay to a Third Party control account established by the
parties within [***] of the Effective Date in accordance with Schedule 7.1(b), for the benefit of
the Product (and owners of Product rights, including S2 and VeroScience), with distributions being
made from such control account as set forth on Schedule 7.1(b), an amount equal to thirty-five
percent (35%) of the Gross Margin (the “Product Royalty”) on a quarterly basis beginning
with the Agreement Quarter during which the first commercial sale of the Product in the Territory
occurs; provided, that after cumulative Gross Margin exceeds One Hundred Million Dollars
($100,000,000.00), the Product Royalty shall be an amount equal to forty percent (40%) of the
Gross Margin. Notwithstanding the foregoing, at any time during the Term prior to the Agreement
Quarter in which the cumulative Gross Margin exceeds [***] ($[***]), S2 may elect to reduce Santarus’ share of the Gross Margin by paying to Santarus a
lump-sum payment of the difference between [***] ($[***]) and [***] of the cumulative Gross Margin
as of the date of payment, in which case the Product Royalty shall be an amount equal to [***] of
the Gross Margin, beginning as of the date such payment is received by Santarus. In addition to
the foregoing, in the event that Net Sales exceed One Hundred Million Dollars ($100,000,000.00) in a given calendar year, S2 and VeroScience, collectively, shall be entitled to
an additional amount equal to three percent (3%) of the Gross Margin, for the time period after
Net Sales exceed One Hundred Million Dollars ($100,000,000.00), with regard to Net Sales in excess
of One Hundred Million Dollars ($100,000,000.00) (“Royalty True-Up”). The Royalty True-Up
shall be calculated at the end of the calendar year and Santarus shall pay to S2 and VeroScience
such Royalty True-Up in accordance with Schedule 7.1(b) within ninety (90) days after the end of
any applicable calendar year.

     (c) [***]

     (d) Within [***] ([***]) business days following the end of each [***] during the Term,
Santarus shall provide S2 and VeroScience with a statement in a mutually agreeable format setting
forth:

               (i) the aggregate number of units of the Product invoiced and recognized as sales to
customers in the Territory during such Agreement Month;

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

27

 

               (ii) gross sales during such Agreement Month (defined as units invoiced and recognized as
sales multiplied by the wholesale acquisition cost, or WAC);

               (iii) Net Sales, including a detailed
accounting of permitted deductions from gross sales during such Agreement Month;

               (iv) COGS during
such Agreement Month; and

               (v) Gross Margin for such Agreement Month.

     (e) Except as expressly
specified otherwise, any amounts payable by Santarus to S2 and VeroScience in respect of any
Agreement Quarter pursuant to this Agreement shall be paid within [***] ([***]) business days after
the end of such Agreement Quarter. Statements required to be provided to S2 and VeroScience under
this Section 7.1 shall be emailed to such email addresses as S2 and VeroScience may from time to
time designate in writing.

     (f) In the event that payments due to S2 or VeroScience under this Agreement for a particular
period would be a negative number, neither S2 nor VeroScience will be required to make a payment to
Santarus for such period, but such negative number shall be credited against future payments due to
S2 and VeroScience hereunder; provided that upon expiration or termination of this Agreement
(except in the event of a termination by S2 or VeroScience pursuant to Section 8.3), S2 or
VeroScience, as applicable, shall promptly pay to Santarus any aggregate negative amounts which
were to be credited as provided hereunder but in no event later than thirty (30) days following the
Final Agreement Quarter.

     (g) In the event adjustment(s) to Gross Margin are made more than [***] ([***]) business days
subsequent to the end of an Agreement Month, such adjustment(s) will be applied to the following
Agreement Month and may result in an adjustment to the payment for such Agreement Quarter.

     (h) For clarity, as between the parties, S2 or VeroScience shall be solely responsible for any
fees or payments required under the Upstream Agreements. Santarus shall have no responsibility for
any such fees or payments.

     7.2 Maintenance of Records

     (a) Santarus agrees to keep, for a period of at least [***] ([***]) years after the date of
entry (or such longer period as may be required by Legal Requirements) full and accurate records
maintained in accordance with Santarus’ accounting practices in sufficient detail to enable a Third
Party to accurately calculate COGS, Gross Margin and Net Sales reported, and payments to be made
under this Agreement. Upon [***] ([***]) days prior written notice, such records shall be made
available by Santarus for audit by an independent certified public accounting firm designated by S2
and VeroScience and reasonably acceptable to Santarus. The auditor will only examine such books and
records during business hours but not more than [***] while this Agreement remains in effect and
for [***] ([***]) years thereafter in order to verify COGS, Gross Margin, Net Sales or payments due
under this Agreement. The fees and expenses

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

28

 

of the auditor performing such verification examination shall be borne by S2 and VeroScience;
provided, however, that if any verification reveals that Santarus has reported incorrectly, and the
amount of such discrepancy is at least [***] percent ([***]%) of the aggregate amount that should
have been reported for the period examined, then Santarus shall pay the entire amount of the fees
and expenses for such verification. This right to audit shall extend throughout the Term and for
[***] after expiration or termination of this Agreement.

     (b) Santarus shall have the right, upon [***] ([***]) business days’ prior written notice, to
audit all applicable records of each other party for the purpose of determining such other party’s
compliance with the obligations set forth in this Agreement. The audit will be conducted during
normal business hours, at convenient times. Any such audit may be conducted no more than [***]. The
fees and expenses of any such audit shall be borne by Santarus. This right to audit shall extend
throughout the Term and for [***] after expiration or termination of this Agreement.

     (c) Whenever in this Agreement a party is required to report its costs, or is entitled to
receive or obligated to make a payment based on its costs, such costs shall be determined in
accordance with generally accepted accounting principles as applied in the United States (“GAAP”),
consistent with the terms of this Agreement. The term “out-of-pocket” costs or expenses means cost
or expenses paid to Third Parties and shall not include any fixed costs or expenses, personnel
costs or expenses, overhead costs or expenses, or other costs or expenses of a similar nature.

     (d) Each of S2 and VeroScience shall prepare, at its sole cost and expense, unaudited
financial statements (including an income statement, balance sheet and a statement of cash flow) in
accordance with S2 and VeroScience’s standard accounting principles, as applicable, and GAAP,
consistently applied, subject to normal year-end audit adjustments [***], on a quarterly and on an
annual basis each calendar year during the Term. Such financial statements shall be provided to
each of the other parties within [***] ([***]) days after each of the first three (3) calendar
quarters of each calendar year and within [***] ([***]) days after the end of each calendar year.

     7.3 Payments

     Any payments required to be made under this Agreement shall be made in United States dollars
via wire transfer of immediately available funds to such bank account as the other party shall
designate in writing prior to the date of such payment. All payments shall bear interest from the
date due until paid at a rate equal to the prime rate effective for the date that payment was due,
as quoted by the Wall Street Journal, New York Edition, on the date such payment was due, plus
[***] percent ([***]%), or, if less, the maximum rate permitted by applicable law.

     7.4 Expenses

     Except as otherwise agreed between the parties or set forth in this Agreement, each party will
bear its own operating expenses associated with the Product and Commercialization

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

29

 

and Promotion thereof, including all personnel, general and administrative and overhead costs. As
between the parties, (a) Santarus will bear all Santarus Sales Force expenses and costs associated
with its Promotion in the Territory and its Manufacturing for Commercialization in the Territory
(provided that S2 and VeroScience will share in certain of these costs as a function of the Gross
Margin split pursuant to Section 7.1(b)), and (b) VeroScience or S2 will bear all costs associated
with Development of the Product, and with maintaining and continuing all Regulatory Approvals, in
each case, in the Territory, including all Regulatory Amounts.

ARTICLE VIII

 TERM AND
TERMINATION

     8.1 Term

     The term of this Agreement shall commence on the Effective Date and shall continue, unless
terminated sooner in accordance with this Article VIII, until Santarus ceases to market or sell the
Product in the Territory (the “Term”).

     8.2 Early Termination

     (a) Santarus may terminate this Agreement on the first anniversary of the first sale for use,
consumption or resale of the Product to a Third Party in a bona fide arm’s-length transaction in
the Territory following the Promotion Commencement Date (“First Commercial Sale”) upon at
least sixty (60) days’ prior written notice to S2 and VeroScience.

     (b) After the first anniversary of the First Commercial Sale, Santarus may terminate this
Agreement for any reason upon one hundred twenty (120) days’ prior written notice to S2 and
VeroScience.

     (c) Santarus may terminate this Agreement immediately upon written notice to S2 and
VeroScience in the event of (i) any action taken or objection raised by any Governmental Authority
that prevents Santarus from performing its obligations under this Agreement, all together or in any
material part, or otherwise makes such activity unlawful, or (ii) approval by FDA of an Abbreviated
New Drug Application, or ANDA, submitted by a Third Party, for which the Product is the reference
product and such approval is for an “AB” rated equivalent to the Product (a “Generic
Product”).

     (d) Santarus may terminate this Agreement immediately in the event of a large scale recall or
withdrawal of the Product from the market in the Territory resulting from a significant safety risk
inherent in the Product and not due to (i) tampering, (ii) a remediable manufacturing problem, or
(iii) other defect that can be cured with respect to Product manufactured after such risk is
discovered.

     8.3 Termination for Cause

     Either S2 or VeroScience, on the one hand, or Santarus, on the other hand, may terminate this
Agreement, effective at any time after providing at least sixty (60) days written notice and an

30

 

opportunity to cure during such sixty (60)-day period, in the event of a material failure of
Santarus, on the one hand, or S2 or VeroScience, on the other hand, to comply with its material
obligations contained in this Agreement. If such cure is effected within such sixty (60) day cure
period, such notice with respect to such termination shall be null and void. Notwithstanding
anything herein to the contrary, in the event that Santarus (a) gives notice of material breach of
this Agreement by S2 pursuant to this Section 8.3, Santarus shall contemporaneously provide a copy
of such notice to VeroScience, or (b) gives notice of material breach of this Agreement by
VeroScience pursuant to this Section 8.3, Santarus shall contemporaneously provide a copy of such
notice to S2. Santarus agrees that, in addition to the right of S2 and VeroScience to cure their
own breach, S2 and VeroScience shall each have the right to cure any material breach by such other
party. Additionally, either S2 or VeroScience may terminate this Agreement immediately if Santarus
or any of its Affiliates directly or indirectly initiate or prosecute any lawsuit or any other
civil or administrative proceeding, or the making of any claim or counterclaim, of any kind in any
court, tribunal, agency or governmental entity anywhere in the world challenging the validity or
enforceability of any VeroScience Patent. For the avoidance of doubt, the failure of S2 and
VeroScience to comply with each of their obligations under Section 4.7, Section 7.4 and ARTICLE V
of this Agreement shall be deemed a material breach of this Agreement.

     8.4 Termination for Bankruptcy or Force Majeure

     To the extent permitted by law, either S2 (on behalf of S2 and VeroScience) or Santarus (with
respect to any event described in this Section 8.4 that is applicable to either S2 or VeroScience)
may terminate this Agreement immediately upon notice to each other party, in the event of either of
the following:

     (a) The entry of an order for relief under the United States Bankruptcy Code (or any
corresponding remedy under successor laws) against another party; the filing of a petition by or
against another party under any bankruptcy, insolvency or similar law (which petition is not
dismissed within sixty (60) days after filing), except Chapter 11 of the United States Bankruptcy
Code or any successor statute that permits a corporation to continue its operation while protecting
it from creditors; the appointment of a receiver for another party’s business or property; or
another party’s making of a general assignment for the benefit of its creditors; or

     (b) Any Force Majeure Event affecting another party beyond such other party’s control which lasts for a period of
at least six (6) months and which is of sufficient intensity to interrupt or prevent the carrying
out of such other party’s material obligations under this Agreement during such period.

     (c) Notwithstanding the occurrence of any of the events specified in subsection (a) of this
Section 8.4, the parties acknowledge and agree that, to the extent Section 365(n) of the United
States Bankruptcy Code applies to this Agreement, the non-insolvent party(ies) may elect to retain
and exercise the rights granted to it hereunder with respect to the intellectual property owned or
controlled by the insolvent party.

31

 

     For clarity, neither S2 nor VeroScience may terminate this Agreement pursuant to this Section
8.4 with respect to any event described in this Section 8.4 that is applicable to either
VeroScience or S2.

     8.5 Effect of Termination

     (a) No additional payment obligations arising under Article VII hereof shall accrue after the
date of expiration or termination of this Agreement except as set forth in Section 7.1(f), 7.2 and
Section 8.5(c)(iv); provided, however, that expiration or termination of this Agreement shall not
relieve any party of any obligations accruing prior to such expiration or termination. Certain
provisions of this Agreement by their terms continue after the expiration or termination of this
Agreement, including Sections 2.4(a), 5.5, 5.6, 5.8, 7.1(f), 7.2, 7.3, 7.4, this Section 8.5, 14.1,
Articles XI, XII, XIII and XV and solely with respect to the reports required for the Final
Agreement Quarter or the final Agreement Month, as the case may be, Sections 4.6(b) and 4.6(c). In
addition, any other provisions required to interpret and enforce the parties’ rights and
obligations under this Agreement shall also survive, but only to the extent required for the full
observation and performance of this Agreement.

     (b) Expiration or termination of this Agreement shall be without prejudice to (i) any remedies
which any party may then or thereafter have hereunder or at law or in equity; and (ii) a party’s
right to receive any payment accrued under the Agreement prior to the termination date but which
became payable thereafter; and (iii) any party’s right to obtain performance of any obligations
provided for in this Agreement which survive expiration or termination by their terms or by a fair
interpretation of this Agreement. Except as expressly set forth herein, the rights to terminate as
set forth herein shall be in addition to all other rights and remedies available under this
Agreement, at law, or in equity or otherwise.

     (c) Upon the expiration or termination of this Agreement pursuant to this Article VIII:

               (i) All rights and licenses granted to Santarus by S2 and VeroScience under this Agreement shall
terminate.

               (ii) Each party shall promptly transfer and return to the applicable party all Proprietary
Information of such party (provided that each party may keep one copy of such Proprietary
Information for the sole purpose of enforcing its rights under this Agreement).

               (iii) S2 may, but is not obligated to, purchase from Santarus, at Santarus’ cost (as
determined pursuant to this Agreement) all remaining Samples and Promotional Materials; provided,
however, that S2 shall be obligated to purchase such Samples from Santarus at cost in the event
that this Agreement is terminated by Santarus pursuant to Sections 8.2(c)(i) or 8.3.

               (iv) Santarus shall have the right to sell its existing inventory of trade Product for a
period of six (6) months following the effective date of termination subject to the payment
obligations of Article VII. S2 may, but is not obligated to, purchase from Santarus, at

32

 

Santarus’ cost, all remaining trade Product; provided, however, that S2 shall be obligated to
purchase such trade Product from Santarus at cost in the event that this Agreement is terminated by
Santarus pursuant to Sections 8.2(c)(i) or 8.3.

               (v) Santarus shall take reasonable actions to transfer to S2 the contents and maintenance of
the Websites.

               (vi) Santarus shall reasonably cooperate with S2 to facilitate orderly transition of
Manufacturing and Commercialization of the Product, including by assigning or otherwise
transferring (to the extent permissible) to S2 Santarus’ rights and obligations under Third Party
contracts exclusively related to such Manufacturing or Commercialization (including the Patheon
Agreement and the Supplemental Patheon Agreements), as reasonably requested by S2. Subject to the
terms and conditions of this Agreement, Santarus shall remain responsible for all liabilities and
obligations accrued, other than for Product delivered to S2 following the Term in accordance
herewith, under such Third Party agreements prior to the effective date of such expiration or
termination.

ARTICLE IX

REPRESENTATIONS AND WARRANTIES

     9.1 Representations and Warranties of S2

     S2 hereby represents and warrants to Santarus and VeroScience as of the date hereof as follows:

     (a) Organization. S2 (i) is a corporation duly organized, validly existing and in good
standing under the laws of the state of Tennessee, and (ii) has all necessary corporate power and
corporate authority to own its properties and to conduct its business, as currently conducted.

     (b) Authorization. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby are within the corporate power of S2, have been duly
authorized by all necessary corporate proceedings of S2, and this Agreement has been duly executed
and delivered by S2.

     (c) No Conflict. The execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby do not: (i) conflict with or result in a breach of any
provision of S2’s organizational documents; (ii) result in a material breach of any material
agreement to which S2 is party; (iii) result in a violation of any Order to which S2 is subject;
(iv) require S2 to obtain any material approval or consent from any Governmental Authority or Third
Party other than those consents and approvals which have been obtained on or prior to the date
hereof; or (v) violate any Legal Requirement applicable to S2 in any material respect.

     (d) Enforceability. This Agreement constitutes the valid and binding obligation of S2,
enforceable against S2 in accordance with its terms, subject to bankruptcy, reorganization,
insolvency and other similar laws affecting the enforcement of creditors’ rights in general and to

33

 

general principles of equity (regardless of whether considered in a proceeding in equity or an
action at law).

     (e) Broker. S2 has not employed any broker, finder, or agent with respect to this
Agreement or the transactions contemplated hereby.

     (f) Intellectual Property. Cycloset as described in NDA No. 20,866 is covered by the
patents listed in the FDA’s Orange Book as of the Effective Date (the “Listed Patents”)
and, to S2’s knowledge, such Listed Patents are valid and enforceable, all maintenance fees have
been paid for the Listed Patents, and neither the Manufacture nor Commercialization in the
Territory in accordance with this Agreement will infringe any patents, trademarks or other
intellectual property rights of any Third Party. S2 has the right, power and authority to grant the
licenses granted by it hereunder. S2 (i) has not received any written claim or demand from any
Third Party alleging that any infringement, violation or misappropriation of such Third Party’s
intellectual property rights has occurred as a result of the manufacture, use, offer for sale, sale
or importation of the Product in the Territory; (ii) is not aware of any actual, alleged or
threatened infringement, violation or misappropriation by a Third Party of any S2 intellectual
property rights covering the Product or its uses; and (iii) has not received any written claim or
demand from any Third Party alleging invalidity or unenforceability of any patents or patent
applications owned or licensed by S2 covering the Product or its uses. To S2’s knowledge, the
VeroScience IP licensed under Section 2.1(a) constitutes all of the intellectual property rights
that are necessary for Santarus to make, have made, use, have used, offer to sell, sell, have sold,
import, have imported and to otherwise Manufacture and Commercialize Cycloset as described in NDA
No. 20,866 under the Product Trademarks in the Field in the Territory.

     (g) Litigation. There is no litigation, arbitration proceeding, governmental
investigation, action or claim of any kind, pending or, to S2’s knowledge, threatened, by or
against S2 or its Affiliates, or, to S2’s knowledge, Patheon or its Affiliates relating to the
Product or which would reasonably be expected to materially affect S2’s ability to perform its
obligations hereunder.

     (h) Documentation. S2 has made available to Santarus copies of all material clinical
data and reports, medical information, competitive information, marketing research, agreements and
other documentation related to the Product in S2’s possession that have been requested by Santarus
in the course of Santarus’ due diligence investigation of the Product.

     (i) Financial Statements. Prior to the Effective Date, S2 has delivered to Santarus
its unaudited income statement, balance sheet, and statement of cash flows for the year ended
December 31, 2009 and its unaudited income statement, balance sheet, and statement of cash flows at
June 30, 2010 and for the six (6) months then ended (the “S2 Financials”). The S2
Financials are complete and correct in all material respects, have been prepared in accordance with
generally accepted accounting principles consistent with methods used in prior periods, and present
fairly the financial condition and operating results of S2 as of the dates and for the periods
indicated, subject to normal year-end audit adjustments and except that the S2 Financials may not
contain all footnotes as would be required by generally accepted accounting principles.

34

 

Except as disclosed in the S2 Financials, S2 does not have any material liability, direct or
contingent, and is not a guarantor or indemnitor of any indebtedness of any other person or entity.
S2 maintains and will continue to maintain a standard system of accounting established and
administered in accordance with generally accepted accounting principles.

     (j) Generic Drug Act. Pursuant to the Generic Drug Enforcement Act of 1992, 21 U.S.C.
§ 335a, as may be amended or supplemented (the “Generic Drug Act”),

               (i) none of S2 or its
Affiliates, or any Person under its direction or control, is currently debarred by the FDA under
the Generic Drug Act;

               (ii) none of S2 or its Affiliates, or any Person under its direction or
control is currently using or will use in any capacity in connection with the Product any Person
that is debarred by FDA under the Generic Drug Act; and

               (iii) there have been no convictions of S2
or its Affiliates, or any Person under its direction or control for any of the types of crimes set
forth in the Generic Drug Act within the five (5) years prior to the Effective Date.

     (k) Legal Requirements. None of S2 or its Affiliates, or any Person under its
direction or control is currently excluded from a federal or state health care program under
Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 as may be amended
or supplemented. None of S2 or its Affiliates, or any Person under its direction or control is
otherwise currently excluded from contracting with the federal government. None of S2 or its
Affiliates, or any Person under its direction or control is otherwise currently excluded,
suspended, or debarred from any federal or state health care program. S2 shall promptly notify
Santarus and VeroScience if, at any time during the Term, S2 or its Affiliates, or any Person under
its direction or control is convicted of an offense that would subject it or Santarus or S2 to
exclusion, suspension, or debarment from any federal or state health care program. The manufacture,
use, offer for sale, sale and importation of the Product in the Territory has been in material
compliance with all Legal Requirements.

     (l) NDA. To S2’s knowledge, the data regarding the efficacy and safety of the Product
contained in the NDA and other regulatory filings submitted to the FDA in support of marketing
approval of the Product are complete and accurate in all material respects.

     (m) Patheon Agreement. S2 has provided to Santarus true, complete and correct copies
of the Patheon Agreement and those certain Capital Expenditure and Equipment Agreement, dated as of
May 26, 2010, between S2 and Patheon, and Quality Agreement, dated as of May 26, 2010, between S2
and Patheon, each as amended from time to time (collectively, the “Supplemental Patheon
Agreements”). The Patheon Agreement and the Supplemental Patheon Agreements are the only
agreements existing as of the Effective Date by which S2 has contracted for supply of the Product
in the Territory or otherwise established logistics for the distribution of the Product in the
Territory. S2 is not in material breach of the Patheon Agreement or the Supplemental Patheon
Agreements and has not submitted to Patheon any

35

 

notice (written or oral) to the effect that Patheon is in breach of the Patheon Agreement or the
Supplemental Patheon Agreements. S2 has not received from Patheon any notice (written or oral) to
the effect that S2 is in breach of the Patheon Agreement or the Supplemental Patheon Agreements.
Each of the Patheon Agreement and the Supplemental Patheon Agreements is legal, valid, binding,
enforceable and in full force and effect (except as enforcement may be affected by bankruptcy,
insolvency or other similar laws and by general principles of equity).

     (n) Upstream Agreements. S2 has provided to Santarus true, complete and correct copies
of each Upstream Agreement. Schedule 1.87 sets forth all written and oral arrangements or
agreements pursuant to which S2 or, to S2’s knowledge, VeroScience, either acquired rights to the
Product or is required to make payments to a Third Party in connection with the Product. S2 is not
in breach of any Upstream Agreement and has not submitted to the counterparty to any such Upstream
Agreement any notice (written or oral) to the effect that such counterparty is in breach of such
Upstream Agreement. S2 has not received from the counterparty to any Upstream Agreement any notice (written or oral) to the effect that S2 is in breach of such Upstream
Agreement. Each of the Upstream Agreements is legal, valid, binding, enforceable and in full force
and effect (except as enforcement may be affected by bankruptcy, insolvency or other similar laws
and by general principles of equity).

     (o) Security Interests. Citizens Bank, a Tennessee corporation, and [***] are the only
parties holding a security interest in the S2/Vero Agreement and this Agreement, and Citizens Bank
is the only party that has filed, or has on record, a financing statement under the UCC (or similar
statement or instrument of registration under the law of any relevant jurisdiction) covering the
S2/Vero Agreement and this Agreement.

     (p) Other Arrangements. This Agreement, together with the schedules and exhibits
hereto, contain all of the terms agreed to by S2 and Santarus regarding the subject matter hereof
and there are no other agreements or arrangements between S2 and Santarus except as provided
herein.

     9.2 Representations and Warranties of VeroScience

     VeroScience hereby represents and warrants to Santarus and S2 as of the date hereof as follows:

     (a) Organization. VeroScience (i) is a limited liability company duly organized,
validly existing and in good standing under the laws of the state of Delaware, and (ii) has all
necessary power and authority to own its properties and to conduct its business, as currently
conducted.

     (b) Authorization. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby are within the power of VeroScience, have been duly
authorized by all necessary proceedings of VeroScience, and this Agreement has been duly executed
and delivered by VeroScience.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

36

 

     (c) No Conflict. The execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby do not: (i) conflict with or result in a breach of any
provision of VeroScience’s organizational documents; (ii) result in a material breach of any
material agreement relating to the Product to which VeroScience is party; (iii) result in a
violation of any Order to which VeroScience is subject; (iv) require VeroScience to obtain any
material approval or consent from any Governmental Authority or Third Party other than those
consents and approvals which have been obtained on or prior to the date hereof; or (v) violate any
Legal Requirement applicable to VeroScience in any material respect.

     (d) Enforceability. This Agreement constitutes the valid and binding obligation of
VeroScience, enforceable against VeroScience in accordance with its terms, subject to bankruptcy,
reorganization, insolvency and other similar laws affecting the enforcement of creditors’ rights in
general and to general principles of equity (regardless of whether considered in a proceeding in
equity or an action at law).

     (e) Broker. VeroScience has not employed any broker, finder, or agent with respect to
this Agreement or the transactions contemplated hereby.

     (f) Intellectual Property. Cycloset as described in NDA No. 20,866 is covered by the
Listed Patents and to VeroScience’s knowledge, the Listed Patents are valid and enforceable. All
maintenance fees have been paid for the Listed Patents. Except for U.S. Patent Number 5,679,685
with respect to which VeroScience holds joint ownership with a Third Party, VeroScience owns or
Controls the entire right, title and interest in and to the Listed Patents to the extent related to
Cycloset as described in NDA No. 20,866, subject to the S2/Vero Agreement and the Upstream
Agreements. To VeroScience’s knowledge, neither the Manufacture or Commercialization in the
Territory in accordance with this Agreement will infringe any patents, trademarks or other
intellectual property rights of any Third Party. VeroScience has the right, power and authority to
grant the licenses granted by it under the S2/Vero Agreement.VeroScience (i) has not received any written claim or demand from any Third Party alleging that any
infringement, violation or misappropriation of such Third Party’s intellectual property rights has
occurred as a result of the manufacture, use, offer for sale, sale or importation of the Product in
the Territory; (ii) is not aware of any actual, alleged or threatened infringement, violation or
misappropriation by a Third Party of any VeroScience intellectual property rights covering the
Product or its uses; and (iii) has not received any written claim or demand from any Third Party
alleging invalidity or unenforceability of any patents or patent applications owned or licensed by
VeroScience covering the Product or its uses. To VeroScience’s knowledge, the VeroScience IP
licensed under Section 2.1(a) constitutes all of the intellectual property rights that are
necessary for Santarus to make, have made, use, have used, offer to sell, sell, have sold, import,
have imported and to otherwise Manufacture and Commercialize Cycloset as described in NDA No.
20,866 under the Product Trademarks in the Field in the Territory.

     (g) Litigation. There is no litigation, arbitration proceeding, governmental
investigation, action or claim of any kind, pending or, to the knowledge of VeroScience,
threatened, by or against VeroScience or its Affiliates or Patheon or its Affiliates relating to
the

37

 

Product or which would reasonably be expected to materially affect VeroScience’s or S2’s ability to
perform its obligations hereunder.

     (h) Documentation. VeroScience has made available to Santarus copies of substantially
all material clinical data and reports, medical information, competitive information, marketing
research, agreements and other documentation related to the Product in VeroScience’s possession
that have been requested by Santarus in the course of Santarus’ due diligence investigation of the
Product.

     (i) Financial Statements. Prior to the Effective Date, VeroScience has delivered to
Santarus its unaudited income statement, balance sheet, and statement of cash flows for the year
ended December 31, 2009 and its unaudited income statement, balance sheet, and statement of cash
flows at August 16, 2010 and for the calendar year to date period then ended (the “VeroScience Financials”). The VeroScience Financials are complete and correct in all material respects, have
been prepared in accordance with generally accepted accounting principles consistent with methods
used in prior periods, and present fairly the financial condition and operating results of
VeroScience as of the dates and for the periods indicated, subject to normal year-end audit
adjustments and [***]. [***] VeroScience maintains and will continue to maintain a standard system
of accounting established and administered in accordance with generally accepted accounting
principles.

     (j) Generic Drug Act. Pursuant to the Generic Drug Act,

               (i) none of VeroScience or its Affiliates, or any Person under its direction or control is
currently debarred by the FDA under the Generic Drug Act;

               (ii) none of VeroScience or its
Affiliates, or any Person under its direction or control is currently using in any capacity in
connection with the Product any Person that is debarred by FDA under the Generic Drug Act; and

               (iii) there have been no convictions of VeroScience or its Affiliates, or any Person under its
direction or control for any of the types of crimes set forth in the Generic Drug Act within the
five years prior to the Effective Date.

     (k) Legal Requirements. None of VeroScience or its Affiliates, or any Person under its
direction or control is currently excluded from a federal or state health care program under
Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 as may be amended
or supplemented. None of VeroScience or its Affiliates, or any Person under its direction or
control is otherwise currently excluded from contracting with the federal government. None of
VeroScience or its Affiliates, or any Person under its direction or control is otherwise currently
excluded, suspended, or debarred from any federal or state health care program. VeroScience shall
promptly notify Santarus and S2 if, at any time during the Term, VeroScience or its Affiliates, or
any Person under its direction or control is convicted of an offense that would subject it or
Santarus or S2 to exclusion, suspension, or debarment from any federal or state health care
program. To VeroScience’s knowledge, the manufacture, use, offer

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

38

 

for sale, sale and importation of the Product in the Territory has been in material compliance with
all Legal Requirements.

     (l) NDA Acquisition. VeroScience has not committed fraud in relation to the filing or
acquisition of the NDA or used unfair methods of competition in connection with such filing or
acquisition, including, in either case, in connection with any data supplied by VeroScience to the
FDA. The parties acknowledge that a breach of this representation is a material failure of a
material obligation and is not subject to cure. The data regarding the efficacy and safety of the
Product contained in the NDA and other regulatory filings submitted to the FDA in support of
marketing approval of the Product are complete and accurate in all material respects.

     (m) Upstream Agreements. VeroScience has provided to Santarus true, complete and
correct copies of each Upstream Agreement to which VeroScience is a party. Schedule 1.87 sets forth
all written and oral arrangements or agreements pursuant to which VeroScience or, to VeroScience’s
knowledge, S2, either acquired rights to the Product or is required to make payments to a Third
Party in connection with the Product. VeroScience is not in breach of any Upstream Agreement and
has not submitted to the counterparty to any such Upstream Agreement any notice (written or oral)
to the effect that such counterparty is in breach of such Upstream Agreement. VeroScience has not
received from the counterparty to any Upstream Agreement any notice (written or oral) to the effect
that VeroScience is in breach of such Upstream Agreement. Each of the Upstream Agreements is legal,
valid, binding, enforceable and in full force and effect (except as enforcement may be affected by
bankruptcy, insolvency or other similar laws and by general principles of equity).

     (n) Other Arrangements. This Agreement, together with the schedules and exhibits
hereto, contains all of the terms agreed to by VeroScience and Santarus regarding the subject
matter hereof and there are no other agreements or arrangements between VeroScience and Santarus
except as provided herein.

     9.3 Representations and Warranties of Santarus

     Santarus hereby represents and warrants to S2 and VeroScience as of the date hereof as follows:

     (a) Organization. Santarus (i) is a corporation duly organized, validly existing and
in good standing under the laws of the state of Delaware, and (ii) has all necessary corporate
power and corporate authority to own its properties and to conduct its business, as currently
conducted.

     (b) Authorization. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby are within the corporate power of Santarus, have been duly
authorized by all necessary corporate proceedings of Santarus, and this Agreement has been duly
executed and delivered by Santarus.

     (c) No Conflict. The execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby do not: (i) conflict with or result in a breach of any
provision of Santarus’ organizational documents; (ii) result in a material breach of

39

 

any material agreement to which Santarus is party; (iii) result in a violation of any Order to
which Santarus is subject; (iv) require Santarus to obtain any material approval or consent from
any Governmental Authority or Third Party other than those consents and approvals which have been
obtained prior to the date hereof; or (v) violate any Legal Requirement applicable to Santarus in
any material respect.

     (d) Enforceability. This Agreement constitutes the valid and binding obligation of
Santarus, enforceable against Santarus in accordance with its terms, subject to bankruptcy
reorganization, insolvency and other similar laws affecting the enforcement of creditors’ rights in
general and to general principles of equity (regardless of whether considered in a proceeding in
equity or an action at law).

     (e) Broker. Santarus has not employed any broker or finder with respect to this
Agreement or the transactions contemplated hereby.

     (f) Santarus Trademarks. The use of the Santarus Trademarks to Promote and sell
Product in the Territory in accordance with this Agreement will not infringe any trademarks or
other intellectual property rights of any Third Party.

     (g) Litigation. There is no litigation, arbitration proceeding, governmental
investigation, action or claim of any kind, pending or, to the knowledge of Santarus, threatened,
by or against Santarus or any of its Affiliates relating to the Product or which would reasonably
be expected to materially affect Santarus’ ability to perform its obligations hereunder.

     (h) Generic Drug Act. Pursuant to the Generic Drug Act,

               (i) none of Santarus or its Affiliates, or any Person under its direction or control is
currently debarred by the FDA under the Generic Drug Act;

               (ii) none of Santarus or its Affiliates, or any Person under its direction or control is
currently using in any capacity in connection with the Product any Person that is debarred by FDA
under the Generic Drug Act; and

               (iii) there have been no convictions of Santarus or its Affiliates, or any Person under its
direction or control for any of the types of crimes set forth in the Generic Drug Act within the
five years prior to the Effective Date.

     (i) Legal Requirements. None of Santarus or its Affiliates, or any Person under its
direction or control is currently excluded from a federal or state health care program under
Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 as may be amended
or supplemented. None of Santarus or its Affiliates, or any Person under its direction or control
is otherwise currently excluded from contracting with the federal government. None of Santarus or
its Affiliates, or any Person under its direction or control is otherwise currently excluded,
suspended, or debarred from any federal or state health care program. Santarus shall promptly
notify S2 and VeroScience if, at any time during the Term, Santarus or its Affiliates, or any
Person under its direction or control is convicted of an offense that would subject it or S2 or

40

 

VeroScience to exclusion, suspension, or debarment from any federal or state health care program.

     (j) Other Arrangements. This Agreement, together with the schedules and exhibits
hereto, contain all of the terms agreed to by Santarus, on the one hand, and either of S2 or
VeroScience, on the other hand, regarding the subject matter hereof and there are no other
agreements or arrangements between Santarus, on the one hand, and either of S2 or VeroScience, on
the other hand, except as provided herein.

ARTICLE X

INTELLECTUAL PROPERTY MATTERS

     10.1 Intellectual Property Prosecution and Maintenance

     VeroScience shall prosecute and maintain the intellectual property in the Territory related to
the Product and necessary to Manufacture and Commercialize in the Territory pursuant to this
Agreement, including the VeroScience Patents, the Listed Patents and the Product Trademarks.
VeroScience shall make available to Santarus (or its designated counsel) copies of patent
application files and shall make available to Santarus (or its designated counsel) all office
actions relating to any patent applications wherein at least one (1) claim is directed to the
Product in those patent applications, and copies of material correspondence with the U.S. Patent
and Trademark Office relating to such patent applications to the extent they relate to the Product
or its use. Santarus shall have the right to comment upon the prosecution of such patent
applications. VeroScience shall, in good faith, consider such comments of Santarus. In addition,
VeroScience shall keep Santarus reasonably informed regarding material developments relating to the
prosecution, maintenance or enforcement of VeroScience’s intellectual property rights related to
the Product outside the Territory that could reasonably be expected to have a material impact on
VeroScience’s intellectual property rights related to the Product in the Territory. For the
avoidance of doubt, VeroScience and S2 shall remain responsible for all expenses relating to the
preparation, filing, prosecution and maintenance of the intellectual property in the Territory
related to the Product and necessary to Manufacture and Commercialize in the Territory pursuant to
this Agreement, including the VeroScience Patents, the Listed Patents, the Product Trademarks and
any copyrights associated with the Promotional Materials. In the event that VeroScience notifies
Santarus that it no longer wishes to prosecute or maintain the intellectual property in the
Territory related to the Product and necessary to Manufacture and Commercialize in the Territory
pursuant to this Agreement, VeroScience shall promptly notify Santarus in writing sufficiently in
advance to any relevant deadline so that Santarus may, at its discretion, assume the responsibility
for the prosecution or maintenance of such intellectual property in its own name and at its sole
expense. In the event that Santarus also decides not to continue the prosecution or maintenance of
such intellectual property, Santarus shall promptly notify S2 in writing sufficiently in advance to
any relevant deadline so that S2 may, at its discretion, assume the responsibility for the
prosecution or maintenance of such intellectual property in its own name and at its sole expense.

41

 

     10.2 Third Party Competition

     In recognition of Santarus’ agreement to exclusively Commercialize in the Territory, in
accordance with the terms and conditions of this Agreement, and subject to Section 2.1(b), S2 and
VeroScience each agree that if S2, VeroScience or any Affiliate thereof grants to any Affiliate or
Third Party a license, covenant not to sue, right of reference, right of supply, other intellectual
property right or other settlement related to the manufacture, use, offer for sale, sale,
importation, marketing or promotion of the Product in the Territory, including any authorized
generic version of the Product covered by the NDA in the Territory, but excluding the licenses
under the S2/Vero Agreement as of the Effective Date, this Agreement and any license granted in
connection with the manufacture of the Product in the Territory for Development or for
Commercialization outside the Territory, then S2 or VeroScience, as applicable, shall obtain
Santarus’ consent in advance of the grant of any such license, covenant not to sue, right of
reference, right of supply, other intellectual property right or other settlement, and as part of
such consent the parties shall negotiate in good faith financial adjustments to this Agreement
adequate to compensate Santarus for any lost market share attributable to sales of the Product in
the Territory by or on behalf of such Third Party or Affiliate, taking into account the
consideration received by S2, VeroScience or any Affiliate thereof for the grant of such rights or
other settlement.

     10.3 Enforcement or Defense of Patent Rights

     (a) If any party shall learn that any Third Party violates the intellectual property rights
owned or Controlled by any party in the Product and/or the Product Trademarks in the Territory, or
that a Third Party has initiated an action (or any counterclaim or defense asserted in any other
action) in the Territory alleging invalidity or unenforceability of any VeroScience Patents, then
the party becoming so informed shall promptly, but in all events within [***] ([***]) days thereof,
notify the other parties to this Agreement of such information. In the event VeroScience receives a
notice under Paragraph IV of the U.S. Federal Drug Price Competition and Patent Term Restoration
Act of 1984, as amended, also known as the Hatch-Waxman Act, with respect to the Product,
VeroScience shall provide Santarus and S2 with written notice of such Paragraph IV notice within
[***] ([***]) business days (each, a “Paragraph IV Notice”).

     (b) If warranted in the opinion of Santarus, after consultation with S2 and VeroScience,
Santarus shall take such legal action (“Enforcement Action”) as is advisable in Santarus’
reasonable opinion to restrain infringement of such patent rights related to the Product or the
Product Trademarks, or to defend any Third Party action alleging invalidity or unenforceability in
the Territory. S2 shall cooperate fully with, and as reasonably requested by, Santarus in any
Enforcement Action, and Santarus shall reimburse S2 for its out-of-pocket expenses incurred in
providing such cooperation. S2 may be represented by counsel of its own selection at its own
expense in any Enforcement Action. If (i) Santarus elects in writing not to bring an Enforcement
Action with respect to the Product in the Territory, (ii) within [***] ([***]) days following a
written request by S2 or VeroScience to do so Santarus fails to bring an Enforcement Action
(provided that in the case of a Paragraph IV Notice, Santarus shall confirm in writing its election
to bring such Enforcement Action no later than [***] ([***]) days following receipt of the
Paragraph IV Notice), or (iii) S2 otherwise fails to bring an Enforcement

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

42

 

Action or take other reasonable action to protect the patent rights related to the Product or the
Product Trademarks in the Territory from such infringement, then, VeroScience shall have the first
right, at its sole discretion, to institute an Enforcement Action in its own name using counsel of
its choice, at its own expense, and with the right to control the course of such Enforcement Action
(and Santarus and S2 shall provide all reasonable assistance, other than financial, to VeroScience
for such Enforcement Action, at VeroScience’s expense, including joining such Enforcement Action if
necessary to maintain the Enforcement Action, and Santarus and S2 shall have the right to join and
participate in the Enforcement Action whether or not such joinder is requested by VeroScience). If
VeroScience elects in writing not to exercise such right, or within [***] ([***]) days following a
written request by S2 to do so VeroScience fails to bring or defend an Enforcement Action, then, in
compliance with the in-license agreement with respect to applicable Product patent rights licensed
from a Third Party, if any, S2 shall have the right, at its sole discretion, to institute an
Enforcement Action in its own name using counsel of its choice, at its own expense, and with the
right to control the course of such Enforcement Action (and VeroScience and Santarus shall provide
all reasonable assistance, other than financial, to S2 for such Enforcement Action, at S2’s
expense, including joining such Enforcement Action if necessary to maintain the Enforcement Action,
and VeroScience and Santarus shall have the right to join and participate in the Enforcement Action
whether or not such joinder is requested by S2); provided, however, that S2 shall obtain
VeroScience’s and Santarus’ consent (not to be unreasonably withheld) in advance of the grant of
any license, covenant not to sue, right of reference, right of supply, other intellectual property
right or other settlement in any Enforcement Action. In each Enforcement Action, each party shall
have the right to fund a portion of the Enforcement Action. Any recovery received as a result of
any Enforcement Action shall be used first to reimburse the parties for their out-of-pocket costs
and expenses (including attorneys’ and professional fees) incurred in connection with such
Enforcement Action (and not previously reimbursed). If such recovery is insufficient to cover all
such costs and expenses of each party, it shall be shared in proportion to the total of such costs
and expenses incurred by each party. Any amounts remaining thereafter, to the extent relating to
the Product in the Territory or an Included Additional Product in the Territory, shall be shared by
the parties [***]. For clarity, S2 and VeroScience shall be responsible to make any payments
required to Third Party Rights Holders out of their share; provided, that neither S2 nor
VeroScience shall be obligated to pay Third Party Rights Holders more than the amounts such parties
receive in connection with such Enforcement Action.

     10.4 Infringement Claims

     (a) If any party shall learn of a claim or assertion that the manufacture, use or sale of the
Product in the Territory infringes or otherwise violates the intellectual property rights of any
Third Party, then the party becoming so informed shall promptly, but in all events within [***]
([***]) days thereof, notify the other parties to this Agreement of the claim or assertion.

     (b) If warranted in the opinion of Santarus, after consultation with S2 and
VeroScience, Santarus shall take such legal action as is advisable in Santarus’ reasonable opinion
to defend such infringement claims in the Territory. S2 shall cooperate fully
with, and as reasonably requested by, Santarus in any such defense, and Santarus shall reimburse S2
for its

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

43

 

out-of-pocket expenses incurred in providing such cooperation. S2 may be represented by counsel of
its own selection at its own expense in any Enforcement Action. If (i) Santarus elects in writing
not to defend any infringement claim with respect to the Product in the Territory, (ii) within
[***] ([***]) days following a written request by S2 or VeroScience to do so Santarus fails to
defend such a claim, or (iii) Santarus otherwise fails to defend an infringement claim or take
other reasonable action to protect the parties’ rights related to the Product, or to abate such
infringement, then, VeroScience shall have the first right, at its sole discretion, to defend such
infringement claim in its own name using counsel of its choice, at its own expense, and with the
right to control the course of such defense (and Santarus and S2 shall provide all reasonable
assistance, other than financial, to VeroScience for such defense, at VeroScience’s expense, and
Santarus and S2 shall have the right to join and participate in the defense of such infringement
claim whether or not such joinder is requested by VeroScience). If VeroScience elects in writing
not to exercise such right, or within [***] ([***]) days following a written request by S2 to do so
VeroScience fails to defend an infringement claim, then, in compliance with the in-license
agreement with respect to applicable Product patent rights licensed from a Third Party, if any, S2
shall have the right, at its sole discretion, to defend an infringement claim in its own name using
counsel of its choice, at its own expense, and with the right to control the course of such defense
(and VeroScience and Santarus shall provide all reasonable assistance, other than financial, to S2
for such defense, at S2’s expense, and VeroScience and Santarus shall have the right to join and
participate in the defense of such infringement claim whether or not such joinder is requested by
S2); provided, however, that S2 shall obtain VeroScience’s and Santarus’ consent (not to be
unreasonably withheld) in advance of the grant of any license, covenant not to sue, right of
reference, right of supply, other intellectual property right or other settlement in any such
infringement claim defense. In each infringement claim defense, each party shall have the right to
fund a portion of the defense. Any recovery received as a result of any defense shall be used first
to reimburse the parties for their out-of-pocket costs and expenses (including attorneys’ and
professional fees) incurred in connection with such defense (and not previously reimbursed). If
such recovery is insufficient to cover all such costs and expenses of each party, it shall be
shared in proportion to the total of such costs and expenses incurred by each party. Any amounts
remaining thereafter, to the extent relating to the Product in the Territory or an Included
Additional Product in the Territory, shall be shared by the parties [***]. For clarity, S2 and
VeroScience shall be responsible to make any payments required to Third Party Rights Holders out of
their share; provided, that neither S2 nor VeroScience shall be obligated to pay Third Party Rights
Holders more than the amounts such parties receive in connection with such Enforcement Action.

ARTICLE XI

INDEMNIFICATION; LIMITS ON LIABILITY

     11.1 Indemnification

     (a) Each party will defend, at its own expense, indemnify and hold harmless each other party
and its Affiliates, and their respective directors, officers, employees, agents and other
representatives, from and against any and all damages, liabilities, losses, costs, and expenses,
including reasonable attorneys’ fees, arising out of any Third Party claim, suit or proceeding

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

44

 

brought against such other party or its Affiliates, and their respective directors, officers,
employees, agents and other representatives, to the extent such claim, suit, or proceeding is based
upon a claim arising out of or relating to (i) any breach or violation of, or failure to perform,
any covenant or agreement made by such indemnifying party in this Agreement, unless waived in
writing by the indemnified party; (ii) any breach of the representations or warranties made by such
indemnifying party in this Agreement; or (iii) the negligence or willful misconduct of the
indemnifying party, except (under any of (i) or (ii)) to the extent arising out of the breach,
violation, failure, negligence or willful misconduct of the indemnified party.

     (b) In addition, each of S2 and VeroScience, severally, but not jointly, will defend, at their
own expense, indemnify and hold harmless Santarus and its Affiliates, and their respective
directors, officers, employees, agents and other representatives, from and against any and all
damages, liabilities, losses, costs, and expenses, including reasonable attorneys’ fees, arising
out of any Third Party claim, suit or proceeding brought against Santarus or its Affiliates, or
their respective directors, officers, employees, agents and other representatives, to the extent
such claim, suit, or proceeding is based upon a claim arising out of or relating to (u)
Development, (v) any claim by (i) [***]; (w) Commercialization by S2, VeroScience or any Third
Party prior to the Promotion Commencement Date or thereafter pursuant to Section 2.1(b); (x) any
agreement related to the VeroScience Patents to which S2 or VeroScience are party, including the
Upstream Agreements; or (y) any claim made by any Person that the Manufacture, Commercialization or
other use or sale of the Product, as it exists on the Effective Date, in the Territory infringes or
misappropriates the patent, trademark, or other intellectual property rights of such Person; or (z)
any Product liability claim made by any person with respect to the Product (other than such claims
which are described in Section 11.1). The indemnified party agrees that it shall promptly notify
the indemnifying party in writing of any such claim or action and give the indemnifying party full
information and assistance in connection therewith. The indemnifying party shall have the sole
right to control the defense and the sole right to settle or compromise any such claim or action,
except that the prior written consent of the indemnified party shall be required in connection with
any settlement or compromise which could (i) place any obligation on or require any action of such
indemnified party; (ii) admit or imply any liability or wrongdoing of such indemnified party; or
(iii) adversely affect the goodwill or public image of such indemnified party. Notwithstanding the
foregoing, the indemnified party may participate therein through counsel of its choice, but the
cost of such counsel shall be borne solely by the indemnified party. The provisions of this Section
11.1 shall survive termination of this Agreement for the applicable statute of limitations (except
as to claims as to which a party has notified the others in writing prior to the expiration of the
applicable statute of limitations, in which event, the indemnifying party’s obligations under this
Section 11.1 shall survive with respect to any such claim until its resolution pursuant to the
terms of this Article XI). In the event that S2 or VeroScience, as the case may be, possesses
insufficient funds to indemnify Santarus pursuant to this Section 11.1(b) for any Third Party
claim, suit or proceeding that has been finally determined or settled through arbitration or by a
court of competent jurisdiction, Santarus shall have the right to offset all damages, liabilities,
losses, costs, and expenses, including reasonable
attorneys’ fees, arising out of any such Third Party claim, suit or proceeding against the
Product Royalty otherwise payable hereunder.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

45

 

     (c) In addition, Santarus will defend, at its own expense, indemnify and hold harmless S2 and
VeroScience, and their Affiliates, and their respective directors, officers, employees, agents and
other representatives, from and against any and all damages, liabilities, losses, costs, and
expenses, including reasonable attorneys’ fees, arising out of any Third Party claim, suit or
proceeding brought against S2 or VeroScience, or their Affiliates, or their respective directors,
officers, employees, agents and other representatives, to the extent such claim, suit, or
proceeding is based upon a claim arising out of or relating to the Manufacturing or
Commercialization of the Product by Santarus or its Affiliates or Third Party contractors in the
Territory following the Effective Date (other than to the extent arising out of claims subject to
S2 or VeroScience indemnification under Sections 11.1(a) or 11.1(b)). The indemnified party agrees
that it shall promptly notify Santarus in writing of any such claim or action and give Santarus
full information and assistance in connection therewith. Santarus shall have the sole right to
control the defense and the sole right to settle or compromise any such claim or action, except
that the prior written consent of the indemnified party shall be required in connection with any
settlement or compromise which could (i) place any obligation on or require any action of such
indemnified party; (ii) admit or imply any liability or wrongdoing of such indemnified party; or
(iii) adversely affect the goodwill or public image of such indemnified party. Notwithstanding the
foregoing, the indemnified party may participate therein through counsel of its choice, but the
cost of such counsel shall be borne solely by the indemnified party. The provisions of this Section
11.1 shall survive termination of this Agreement for the applicable statute of limitations (except
as to claims as to which a party has notified the others in writing prior to the expiration of the
applicable statute of limitations, in which event, Santarus’s obligations under this Section 11.1
shall survive with respect to any such claim until its resolution pursuant to the terms of this
Article XI).

     11.2 Consequential Damages

     EXCEPT AS SET FORTH HEREIN, NO PARTY (WHICH FOR THE PURPOSES OF THIS SECTION 11.2 SHALL
INCLUDE THEIR RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS) SHALL HAVE ANY
LIABILITY TO ANY OTHER PARTY FOR ANY PUNITIVE DAMAGES, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR
INDIRECT DAMAGES (INCLUDING, BUT NOT LIMITED TO, DAMAGES FOR LOST PROFITS), RELATING TO OR ARISING
FROM THIS
AGREEMENT, EVEN IF SUCH DAMAGES MAY HAVE BEEN FORESEEABLE;
PROVIDED THAT SUCH LIMITATION SHALL NOT APPLY IN THE CASE OF A PARTY’S INDEMNIFICATION OBLIGATIONS
UNDER SECTION 11.1 WITH RESPECT TO SUCH DAMAGES CLAIMED BY A THIRD PARTY, IN THE CASE OF FRAUD OR
WILLFUL MISCONDUCT OR A BREACH OF THE PROVISIONS OF ARTICLE XII OR SECTION 2.4.

46

 

ARTICLE XII

CONFIDENTIALITY AND PUBLICITY

     12.1 Proprietary
Information

     Pursuant to this Agreement, a party receiving Proprietary Information, directly or indirectly,
will treat such Proprietary Information as confidential, will use such Proprietary Information only
for the purposes of this Agreement and will not disclose, and will take all reasonable precautions
to prevent the disclosure of, such Proprietary Information to (a) any of its officers, directors,
managers, equity holders, investors, potential investors, employees, agents, representatives,
Affiliates, sublicensors, subcontractors or consultants, except those who reasonably need to know
such Proprietary Information and who are bound by a like obligation of confidentiality or (b) to
any other Third Parties.

     12.2 Disclosures Required by Law

     In the event a party receiving Proprietary Information is required under applicable Legal
Requirements to disclose such Proprietary Information of the disclosing party to any Governmental
Authority to obtain any Regulatory Approval for the Product, is required to disclose Proprietary
Information in connection with bona fide legal process (including in connection with any bona fide
dispute hereunder) or is required to disclose Proprietary Information under the rules of the
securities exchange upon which its securities are traded, the recipient party may do so only if it
limits disclosure to that purpose after giving the disclosing party prompt written notice of any
instance of such a requirement in reasonable time for the disclosing party to attempt to object to
or to limit such disclosure. In the event of disclosures required under applicable Legal
Requirements, the recipient party shall cooperate with the disclosing party as reasonably requested
thereby.

     12.3 Publicity

     The parties have agreed upon the form and content of a press release to be issued by the
parties promptly following the execution of this Agreement. Once such press release or any other
written statement is approved for disclosure by each party, a party may make subsequent public
disclosure of the contents of such statement without the further approval of any other party. Any
other publicity, news release, public comment or other public announcement, whether to the press,
or otherwise, relating to this Agreement, shall first be reviewed and approved by each party,
except no such approval shall be required for such publicity, news release, public comment or other
public announcement which, in accordance with the advice of legal counsel to the party making such
disclosure, is required by law or for appropriate market disclosure; provided, however, that each
party shall be entitled to refer publicly to the relationship of the parties reflected in this
Agreement (i.e., VeroScience as the owner and developer of the Product, Santarus as the owner of
exclusive marketing and manufacturing rights to the Product in the Territory) in a manner that is
consistent with a press release issued by mutual agreement of the parties. For clarity, any party
making any announcement which is required by law will, unless prohibited by law, give the other
parties an opportunity to review the form and content of such announcement and comment before it is
made. Without limiting anything else contained herein to the contrary, the parties shall work
together to coordinate filings with governmental agencies as to the contents and existence of this
Agreement as the parties shall reasonably deem necessary or appropriate, including the United
States Securities and Exchange Commission, and each party shall provide each other party an
opportunity to comment on any proposed filings, including

47

 

redactions thereto. The provisions of this Article XII shall survive termination of this Agreement
and shall remain in effect until a date [***] ([***]) years after the Term.

     12.4 Publications

     Santarus, on the one hand, and VeroScience and S2, on the other hand, will reasonably
coordinate during the Term with regard to any proposed publications relating directly to the
Product or any Included Additional Product. VeroScience and its Affiliates shall have the right to
make disclosures pertaining to the Product and any Included Additional Product, subject to the
prior review and comment by Santarus and S2 as follows: VeroScience shall provide a copy of any
such proposed abstract, manuscript, or presentation, to the extent relating directly to the Product
or an Included Additional Product, to Santarus and S2 no less than [***] ([***]) calendar days
prior to VeroScience’s intended submission for publication. Santarus and S2 shall respond in
writing promptly and in no event later than [***] ([***]) calendar days after receipt of the
proposed material, with one or both of the following: (a) comments on the proposed material, or (b)
an identification of Santarus’ or S2’s Proprietary Information, as applicable, that is contained in
the material reviewed. With respect to any Proprietary Information of Santarus or S2, such
Proprietary Information shall be deleted from the proposed publication at the request of Santarus
or S2, as applicable. In the case of conference abstracts and other rapid scientific
communications, the parties will use reasonable efforts to complete the review process in [***]
([***]) business days or less. To the extent that Santarus has a proposed publication, Santarus
shall provide S2 and VeroScience with the timely opportunity to review and comment on such proposed
publication, subject to the process as set forth above but applicable to Santarus instead of
VeroScience. Santarus’s right to publish under this Section 12.4 shall be limited to information
directly related to the Product, and shall at all times be subject to VeroScience’s first right to
publish any such information and to the confidentiality obligations hereof.

     12.5 Relationship to Confidentiality Agreements

     This Agreement supersedes the Confidentiality Agreements between the parties, provided that
all confidential information disclosed or received by the parties thereunder shall be deemed
“Proprietary Information” hereunder and shall be subject to the terms and conditions of this
Agreement.

ARTICLE XIII

NOTICES

     13.1 Notices

     All notices required or permitted hereunder shall be given in writing and sent by confirmed
facsimile transmission during normal business hours, or mailed postage prepaid by certified or
registered mail (return receipt requested), or sent by a nationally recognized express courier
service, or hand-delivered at the following address:

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

48

 

If to S2:

S2 Therapeutics, Inc.

302 Rosedale Lane

Bristol, TN 37620

Attention: Charles P. Sutphin, CEO

Fax No.: 276-928-1220

With a copy to (which shall not constitute notice hereunder):

Hogan Lovells US LLP

100 International Drive, Suite 2000

Baltimore, MD 21202

Attention: Asher M. Rubin

Facsimile: 410-659 2701

If to VeroScience:

VeroScience, LLC

1334 Main Road

Tiverton, RI 02878

Attention: Anthony Cincotta, Ph.D.

Fax No.: 401-624-7630

With a copy to (which shall not constitute notice hereunder):

Wiggin and Dana LLP

One Century Tower

New Haven, CT 06508-1832

Attention: Merton G. Gollaher

Facsimile: 203-782-2889

If to Santarus:

Santarus, Inc.

3721 Valley Centre Drive

Suite 400

San Diego, California 92130

Attn: Legal Affairs Department

Facsimile: (858) 314-5702

49

 

With a copy to (which shall not constitute notice

hereunder):

Latham & Watkins LLP

12636 High Bluff Drive, Suite 400

San Diego, California 92130

Attention: Faye H. Russell

Fax No: (858) 523-5450

All notices shall be deemed made upon receipt by the addressee as evidenced by the applicable
written receipt or on the following business day, with respect to a confirmed facsimile not sent
during normal business hours.

ARTICLE XIV

INSURANCE

     14.1 Insurance

     (a) During the Term and for a period of [***] ([***]) years after any expiration or
termination of this Agreement, (i) Santarus shall maintain (A) a commercial general liability
insurance policy or policies with minimum limits of $[***] per occurrence and $[***] in the
aggregate on an annual basis and (B) a product liability insurance policy or policies with minimum
limits of $[***] per occurrence and $[***] in the aggregate on an annual basis; and (ii) each of S2
and VeroScience shall maintain (A) a commercial general liability insurance policy or policies with
minimum limits of $[***] per occurrence and $[***] in the aggregate on an annual basis and (B) a
product liability insurance policy or policies with minimum limits of $[***] per occurrence and
$[***] in the aggregate on an annual basis; provided, however, that upon S2’s exercise of the S2
Co-Promotion Right, S2 shall maintain (A) a commercial general liability insurance policy or
policies with minimum limits of $[***] per occurrence and $[***] in the aggregate on an annual
basis and (B) a product liability insurance policy or policies with minimum limits of $[***] per
occurrence and $[***] in the aggregate on an annual basis.

     (b) Each party shall name each of the other parties as an “additional insured” on all
commercial and product liability policies relating to the insurance described in Section 14.1(a).
Upon request, each party shall provide certificates of insurance to the others evidencing the
coverage specified herein. No party’s liability to the others is in any way limited to the extent
of its insurance coverage.

ARTICLE XV

MISCELLANEOUS

     15.1 Headings

     The titles, headings or captions and paragraphs in this Agreement are for convenience only and
do not define, limit, extend, explain or describe the scope or extent of this Agreement or any of
its terms or conditions and therefore shall not be considered in the interpretation, construction
or application of this Agreement.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

50

 

     15.2 Severability

     In the event that any of the provisions or a portion of any provision of this Agreement is
held to be invalid, illegal, or unenforceable by a Governmental Authority, such provision or
portion of provision will be construed and enforced as if it had been narrowly drawn so as not to
be invalid, illegal, or unenforceable, and the validity, legality, and enforceability of the
enforceable portion of any such provision and the remaining provisions will not be adversely
affected thereby.

     15.3 Entire Agreement

     This Agreement, together with the schedules and exhibits hereto, all of which are incorporated
by reference, contains all of the terms agreed to by the parties regarding the subject matter
hereof and supersedes any prior agreements, understandings, or arrangements between them, whether
oral or in writing. No party shall enter into any agreement that modifies the terms of this
Agreement without the prior written consent of each of the other parties, including any amendment
to or waiver under the S2/Vero Agreement (except as permitted under Section 6.6).

     15.4 Amendments

     This Agreement may not be amended, modified, altered, or supplemented except by means of a
written agreement or other instrument executed by each of the parties hereto. No course of conduct
or dealing between the parties will act as a modification or waiver of any provisions of this
Agreement.

     15.5 Counterparts

     This Agreement may be executed in any number of counterparts (including by facsimile or
electronic signature), each of which will be deemed an original as against the party whose
signature appears thereon, but all of which taken together will constitute but one and the same
instrument.

     15.6 Waiver

     The failure of any party to enforce or to exercise, at any time or for any period of time, any
term of or any right arising pursuant to this Agreement does not constitute, and will not be
construed as, a waiver of such term or right, and will in no way affect that party’s right later to
enforce or exercise such term or right.

     15.7 Force Majeure

     (a) In the event of any failure or delay in the performance by a party of any provision of
this Agreement due to acts beyond the reasonable control of such party (such as, for example, fire,
explosion, strike or other difficulty with workmen, shortage of transportation equipment, accident,
act of God, declared or undeclared wars, acts of terrorism, or compliance with or other action
taken to carry out the intent or purpose of any law or regulation, but not any failure of

51

 

such party to perform under a Third Party agreement) (a “Force Majeure Event”), then such party
shall have such additional time to perform as shall be reasonably necessary under the
circumstances. In the event of such failure or delay, the affected party will use its diligent
efforts, consistent with sound business judgment and to the extent permitted by law, to correct
such failure or delay as expeditiously as possible. In the event that a party is unable to perform
by a reason described in this Section 15.7, its obligation to perform under the affected provision
of this Agreement shall be suspended during such time of nonperformance.

     (b) No party shall be liable hereunder to another party nor shall be in breach for failure to
perform its obligations caused by a Force Majeure Event. In the case of any such event, the
affected party shall promptly, but in no event later than [***] ([***]) days of its occurrence,
notify the other parties stating the nature of the condition, its anticipated duration and any
action being taken to avoid or minimize its effect. Furthermore, the affected party shall keep the
other parties reasonably informed of the efforts to resume performance. After [***] ([***]) days
of such inability to perform, the parties agree to meet and in good faith discuss how to proceed.
In the event that the affected party is prevented from performing its obligations pursuant to this
Section 15.7 for a period of [***] ([***]) months, the other parties shall have the right to
terminate this Agreement pursuant to the provisions of Section 8.4(b).

     (c) Under no circumstances shall a Supply Failure be considered a Force Majeure Event unless
and only to the extent such Supply Failure is attributable to a Force Majeure Event.

     15.8 Successors and Assigns

     Subject to Section 15.9, this Agreement shall be binding upon and shall inure to the benefit
of the parties hereto and their respective successors and assigns permitted under this Agreement.

     15.9 Assignment

     This Agreement and the rights granted herein shall not be assignable (or otherwise
transferred) by any party hereto without the prior written consent of the other parties. Any
attempted assignment without consent shall be void. Notwithstanding the foregoing, a party may
transfer, assign or delegate its rights and obligations under this Agreement without consent to
(a) an Affiliate reasonably capable of performing such party’s obligations under this Agreement or
(b) a successor to all or substantially all of its business or assets of the assigning party to
which this Agreement relates, whether by sale, merger, consolidation, acquisition, transfer,
operation of law or otherwise or (c) in the case of Santarus, to one or more Persons providing
financing to such party pursuant to the terms of a security agreement relating to such financing.
Notwithstanding anything contained herein to the contrary, each of VeroScience and Santarus shall
have the right to engage Third Party subcontractors (including academic collaborators) to perform
services in connection with the performance by such party of its obligations hereunder, without
the consent of S2 or the other party, and may assign or sublicense to such Third Parties such
rights hereunder as are reasonably necessary for the performance of such services by such Third
Parties; provided, with respect to each such subcontract, that (a) the contracting party shall

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

52

 

ensure that each of its subcontractors accepts and complies with all applicable terms and
conditions of this Agreement, (b) the contracting party shall remain responsible for the
performance of its subcontractors hereunder, and (c) any such subcontract shall (i) be subject and
subordinate to the terms and conditions of this Agreement, (ii) contain terms and conditions which
are consistent with the terms and conditions of this Agreement, and (iii) not in any way diminish,
reduce or eliminate any of the contracting party’s obligations under this Agreement.

     15.10 Construction

     The parties acknowledge and agree that: (a) each party and its representatives have reviewed
and negotiated the terms and provisions of this Agreement and have contributed to its revision;
and (b) the terms and provisions of this Agreement will be construed fairly as to each party
hereto and not in favor of or against any party regardless of which party was generally
responsible for the preparation or drafting of this Agreement. Unless the context of this
Agreement otherwise requires: (i) words of any gender include each other gender; (ii) words using
the singular or plural number also include the plural or singular number, respectively; (iii) the
terms “hereof,” “herein,” “hereby,” and derivative or similar words refer to this entire
Agreement; (iv) the terms “Article,” “Section,” “Exhibit,” “Schedule,” or “clause” refer to the
specified Article, Section, Exhibit, Schedule, or clause of this Agreement; (v) “or” is
disjunctive but not necessarily exclusive; and (vi) the term “including” or “includes” means
“including without limitation” or “includes without limitation.” Whenever this Agreement refers to
a number of days, such number shall refer to calendar days unless business days are specified.

     15.11 Governing Law

     This Agreement will be construed under and in accordance with, and governed in all respects
by, the laws of the State of New York, without regard to its conflicts of law principles.

     15.12 Decision-Making; Dispute Resolution

     The parties recognize that a bona fide dispute as to certain matters may from time to time
arise during the Term that relate to a party’s rights or obligations hereunder, including a
dispute arising out of or relating to the interpretation of any provisions of this Agreement or
the failure of a party to perform or comply with any obligation of such party pursuant to this
Agreement or the breach, termination or validity hereof (a “Dispute”). Unless otherwise
set forth in this
Agreement, in the event of a Dispute arising under this Agreement among the parties, any party may
refer such Dispute to the Executive Officers for a decision. The Executive Officers shall
diligently and in good faith attempt to resolve the referred Dispute expeditiously and, in any
event, within [***] ([***]) days of receiving such written notification. In the event that the
Executive Officers are unable to reach a unanimous decision regarding any referred Dispute within
the [***] ([***])-day period, then such Dispute shall be finally settled by binding arbitration,
such arbitration to be conducted in accordance with the provisions set forth in Schedule
15.12. Each party shall participate in any such arbitration proceeding unless otherwise agreed
by each Executive Officer. Except as otherwise set forth in this Agreement, the procedures
specified in Schedule 15.12 shall be the sole and exclusive procedures for the

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect
to the omitted portions.

53

 

resolution of disputes between the parties arising out of or relating to this Agreement; provided,
that a party, without prejudice to such procedures, may seek injunctive relief or other provisional
judicial relief if in its sole judgment such action is necessary to avoid irreparable damage.
Despite such action, the parties will continue to participate in good faith in the procedures
specified in Schedule 15.12. Each party is required to continue to perform its obligations
under this Agreement pending final resolution of any such Dispute.

     15.13 Equitable Relief

     Each party acknowledges that a breach by it of the provisions of this Agreement may not
reasonably or adequately be compensated in damages in an action at law and that such a breach may
cause the other party(ies) irreparable injury and damage. By reason thereof, each party agrees that
the other parties are entitled to seek, in addition to any other remedies they may have under this
Agreement or otherwise, preliminary and permanent injunctive and other equitable relief to prevent
or curtail any breach of this Agreement by another party; provided, however, that no specification
in this Agreement of a specific legal or equitable remedy will be construed as a waiver or
prohibition against the pursuing of other legal or equitable remedies in the event of such a
breach. Each party agrees that the existence of any claim, demand, or cause of action of it against
another party predicated upon this Agreement will not constitute a defense to the enforcement by
another party, or its successors or assigns, of the covenants contained in this Agreement.

     15.14 Relationship Between Parties

     The parties hereto are acting and performing as independent contractors, and nothing in this
Agreement creates the relationship of partnership, joint venture, sales agency, or principal and
agent. No party is the agent of another party hereunder, and no party may hold itself out as such
to any other Person. Except as specifically provided herein, all financial obligations associated
with each party’s business will be the sole responsibility of such party.

[Signature page follows]

54

 

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in
triplicate on the day and year first above written.

	 	 	 	 	 
	 	S2 THERAPEUTICS, INC.

 	 
	 	/s/ Charles P. Sutphin
 	 
	 	By:                         Charles P. Sutphin 	 
	 	Its:                        President and Chief Executive Officer 	 
	 
	 	VEROSCIENCE, LLC

 	 
	 	/s/                         Anthony H. Cincotta, Ph.D.
 	 
	 	By:                         Anthony H. Cincotta, Ph.D. 	 
	 	Its:                        President and Chief Science Officer 	 
	 
	 	SANTARUS, INC.

 	 
	 	/s/ Gerald T. Proehl
 	 
	 	By:                         Gerald T. Proehl 	 
	 	Its:                        President and Chief Executive Officer 	 
	 

55

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]